Pharmaceutical compositions of humanized anti-CD40 antibodies and uses thereof

A humanized anti-CD40 antibody, like KPL-404, addresses the limitations of existing rheumatoid arthritis treatments by blocking the CD40-CD154 interaction, providing effective symptom relief and disease management in patients with inadequate responses to DMARDs or JAKi.

JP2024542148AInactive Publication Date: 2024-11-13キニクサ·ファーマシューティカルズゲゼルシャフト·ミット·ベシュレンクテル·ハフツング
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
JP2024526968
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-02-24
Filing Date
2022-11-01
Publication Date
2024-11-13
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current treatments for rheumatoid arthritis, including disease-modifying antirheumatic drugs (DMARDs) and Janus kinase inhibitors (JAKi), fail to effectively manage the disease in a significant portion of patients, leading to inadequate responses or intolerance, necessitating the development of alternative therapeutic approaches.

Method used

Administration of a humanized anti-CD40 antibody or its antigen-binding fragment, such as KPL-404, which blocks the CD40-CD154 interaction to suppress immune system activation, potentially combined with other therapeutic agents like DMARDs or JAK inhibitors, in specific dosing regimens tailored to individual patient responses.

Benefits of technology

The anti-CD40 antibody therapy demonstrates significant reductions in disease activity scores and symptom severity in rheumatoid arthritis patients, offering an effective treatment option for those non-responsive or intolerant to conventional therapies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024542148000001_ABST
    Figure 2024542148000001_ABST
Patent Text Reader

Abstract

Suppression of the immune system, particularly the humoral immune system, is beneficial in organ transplantation and the treatment of autoimmune diseases such as rheumatoid arthritis. The present disclosure relates to administration regimens for pharmaceutical compositions of anti-CD40 antibodies, such as humanized anti-CD40 antibodies, and their use in the treatment of rheumatoid arthritis.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] (Sequence Description) This application contains a sequence listing filed electronically in Extensible Markup Language (XML) format, which is incorporated herein by reference in its entirety. Said XML copy, created on October 31, 2022, is named 51383-005WO3_Sequence_Listing_10_31_22.XML and is 20,949 bytes in size. [Background technology]

[0002] Suppression of the immune system, particularly the humoral immune system, is beneficial in organ transplantation and the treatment of autoimmune diseases such as rheumatoid arthritis.

[0003] One target for suppressing the immune system is the CD40 / CD154 interaction. CD40 is mainly expressed on the surface of B lymphocytes and other antigen-presenting cells (APCs), such as dendritic cells and macrophages. CD154 is mainly expressed on the surface of T cells. The interaction between these two proteins is associated with B cell activation, which induces cytokine expression and the expression of cell surface markers, including CD23, CD80 and CD86. Antibodies (e.g., humanized antibodies) that target the CD40 / CD154 interaction have been developed.

[0004] There is a need for effective therapeutic regimens for the treatment of rheumatoid arthritis. Summary of the Invention

[0005] In a first aspect, a pharmaceutical composition comprising a humanized anti-CD40 antibody or an antigen-binding fragment thereof, the antibody having a heavy chain variable region having an amino acid sequence having at least 80% (e.g., at least 85%, 90%, 95%, 97%, 99%, or 100%) sequence identity to the amino acid sequence set forth in SEQ ID NO:9 and a light chain variable region having an amino acid sequence having at least 80% (e.g., at least 85%, 90%, 95%, 97%, 99%, or 100%) sequence identity to the amino acid sequence set forth in SEQ ID NO:10, is administered intravenously or subcutaneously or injected into a subject in need of treatment for rheumatoid arthritis, thereby preventing or reducing rheumatoid arthritis in the joints. The method is characterized in that the antibody or antigen-binding fragment thereof is administered at a dosage of about 1 mg / kg to about 20 mg / kg, for example, about 1 mg / kg to about 10 mg / kg (e.g., about 2 mg / kg to about 10 mg / kg, for example, about 1 mg / kg, 1.5 mg / kg, 2 mg / kg, 2.5 mg / kg, 3 mg / kg, 3.5 mg / kg, 4 mg / kg, 4.5 mg / kg, 5 mg / kg, 10 mg / kg, 11 mg / kg, 12 mg / kg, 13 mg / kg, 14 mg / kg, 15 mg / kg, 16 mg / kg, 17 mg / kg, 18 mg / kg, 19 mg / kg, or 20 mg / kg).

[0006] In some embodiments, the pharmaceutical composition administered to a subject comprises an antibody or antigen-binding fragment thereof at a concentration of about 100 mg / mL to about 300 mg / mL, optionally in a volume of about 1.0 to 2.0 mL.

[0007] In some embodiments, the antibody or antigen-binding fragment thereof is administered at a concentration of about 200 mg / mL.

[0008] In some embodiments, a volume of about 0.5 mL to about 5.0 mL (e.g., 0.5 mL, 0.6 mL, 0.7 mL, 0.8 mL, 0.9 mL, 1.0 mL, 1.1 mL, 1.2 mL, 1.3 mL, 1.4 mL, 1.5 mL, 1.6 mL, 1.7 mL, 1.8 mL, 1.9 mL, 2.0 mL, 3.0 mL, 4.0 mL, or 5.0 mL) of the composition is administered to the subject. In some embodiments, a volume of about 1.0 mL is administered.

[0009] The antibody or antigen-binding fragment thereof can be administered at a dosage of about 1 mg / kg to about 20 mg / kg, for example, about 1 mg / kg to about 10 mg / kg (e.g., about 2 mg / kg to about 10 mg / kg, for example, about 1 mg / kg, 1.5 mg / kg, 2 mg / kg, 2.5 mg / kg, 3 mg / kg, 3.5 mg / kg, 4 mg / kg, 4.5 mg / kg, 5 mg / kg, 6 mg / kg, 7 mg / kg, 8 mg / kg, 9 mg / kg, 10 mg / kg, 11 mg / kg, 12 mg / kg, 13 mg / kg, 14 mg / kg, 15 mg / kg, 16 mg / kg, 17 mg / kg, 18 mg / kg, 19 mg / kg, or 20 mg / kg), for example, once a week, once every two weeks, or once a month. In some embodiments, the composition is administered to a subject in a volume of about 0.1 mL to about 2.0 mL (e.g., 0.1 mL, 0.2 mL, 0.3 mL, 0.4 mL, 0.5 mL, 0.6 mL, 0.7 mL, 0.8 mL, 0.9 mL, 1.0 mL, 1.1 mL, 1.2 mL, 1.3 mL, 1.4 mL, 1.5 mL, 1.6 mL, 1.7 mL, 1.8 mL, 1.9 mL, or 2.0 mL, e.g., about 1.0 mL), and the antibody or antigen-binding fragment thereof is administered to a subject in a volume of about 100 mg / mL to about 300 mg / mL (e.g., The compound is present in the composition at a concentration of about 100 mg / mL, 110 mg / mL, 120 mg / mL, 130 mg / mL, 140 mg / mL, 150 mg / mL, 160 mg / mL, 170 mg / mL, 180 mg / mL, 190 mg / mL, 200 mg / mL, 210 mg / mL, 220 mg / mL, 230 mg / mL, 240 mg / mL, 250 mg / mL, 260 mg / mL, 270 mg / mL, 280 mg / mL, 290 mg / mL, or 300 mg / mL, e.g., about 200 mg / mL).

[0010] In some embodiments, the pharmaceutical composition comprises, in addition to the antibody or antigen-binding fragment thereof (e.g., at a concentration of about 100 to 300 mg / mL and optionally in a volume of about 0.5 mL to 3.0 mL), sodium acetate, arginine, glutamate, polysorbate 20. For example, the pharmaceutical composition may comprise sodium acetate in an amount of about 5 mM to about 100 mM (e.g., about 10 mM to about 90 mM, e.g., about 25 mM to about 75 mM, e.g., about 40 mM to about 60 mM, e.g., about 45 mM to about 55 mM, e.g., about 5 mM, 10 mM, 20 mM, 30 mM, 40 mM, 50 mM, 60 mM, 70 mM, 80 mM, 90 mM, or 100 mM, etc., particularly about 50 mM), about 1 mM to about 200 mM (e.g., about 50 mM to about 150 mM, e.g., about 70 mM to about 100 mM), or about 20 mM (e.g., about 25 mM to about 75 mM, e.g., about 40 mM to about 60 mM, e.g., about 45 mM to about 55 mM, e.g., about 5 mM, 10 mM, 20 mM, 30 mM, 40 mM, 50 mM, 60 mM, 70 mM, 80 mM, 90 mM, or 100 mM, etc., particularly about 50 mM). Arginine in an amount of 5 mM to about 125 mM, for example, about 90 mM to about 110 mM, for example, about 95 mM to about 105 mM, for example, about 1 mM, 2 mM, 3 mM, 4 mM, 5 mM, 10 mM, 20 mM, 30 mM, 40 mM, 50 mM, 60 mM, 70 mM, 80 mM, 90 mM, 100 mM, 110 mM, 120 mM, 130 mM, 140 mM, 150 mM, 160 mM, 170 mM, 180 mM, 190 mM, or 200 mM, in particular about 100 mM), 1 mM to about 200 mM (e.g., about 50 mM to about 150 mM, for example, about 75 mM to about 125 mM, for example, about 90 mM to about 110 mM, for example, about 95 mM to about 105 mM, for example, about 1 mM, 2 mM, 3 mM, 4 mM, 5 mM, 10 mM, 20 mM, 30 mM, 40 mM, 50 mM, 60 mM, 70 mM, 80 mM, 90 mM, 100 mM, 110 mM, 120 mM, 130 mM, 140 mM, 150 mM, 160 mM, 170 mM, 180 mM, 190 mM, Glutamate in an amount of about 0.001% to about 0.1% (e.g., about 0.002%, 0.003%, 0.004%, 0.005%, 0.006%, 0.007%, 0.008%, 0.009%, 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, or 0.1%, particularly about 0.01% or about 0.02%). The pharmaceutical composition may have a pH of about 5.0 to 6.0, for example a pH of 5.4.

[0011] In some embodiments, the pharmaceutical composition comprises polysorbate 20, acetate, and one or more polar excipients. The polar excipient may be or may include, for example, a sugar, a polyol, or an amino acid. In some embodiments, the sugar is, for example, sucrose, trehalose, fructose, lactose, dextrose, or mannitol. In some embodiments, the polyol is, for example, polyethylene glycol or sorbitol. In some embodiments, the amino acid is one or more of alanine, arginine, aspartic acid, asparagine, carnitine, citrulline, ornithine, glycine, glutamic acid, glutamine, glycine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tyrosine, and valine. The acetate may include, for example, sodium acetate (e.g., in the form of a salt) or acetate ion in its ionic form.

[0012] In some embodiments, the pharmaceutical composition comprises about 5 mM to about 100 mM (e.g., about 10 mM to about 90 mM, e.g., about 25 mM to about 75 mM, e.g., about 40 mM to about 60 mM, e.g., about 45 mM to about 55 mM, e.g., about 5 mM, 10 mM, 20 mM, 30 mM, 40 mM, 45 mM, 50 mM, 60 mM, 70 mM, 80 mM, 90 mM, or 100 mM) acetate. In some embodiments, the pharmaceutical composition comprises about 50 mM acetate.

[0013] In some embodiments, the pharmaceutical composition comprises about 1 mM to about 200 mM (e.g., about 50 mM to about 150 mM, e.g., about 75 mM to about 125 mM, e.g., about 90 mM to about 110 mM, e.g., about 95 mM to about 105 mM, e.g., about 1 mM, 2 mM, 3 mM, 4 mM, 5 mM, 10 mM, 20 mM, 30 mM, 40 mM, 50 mM, 60 mM, 70 mM, 80 mM, 90 mM, 100 mM, 110 mM, 120 mM, 130 mM, 140 mM, 150 mM, 160 mM, 170 mM, 180 mM, 190 mM, or 200 mM) of a polar excipient. In some embodiments, the pharmaceutical composition comprises about 50 mM of a polar excipient. In some embodiments, the pharmaceutical composition comprises about 100 mM of a polar excipient. In some embodiments, the pharmaceutical composition comprises about 150 mM of a polar excipient. In some embodiments, the pharmaceutical composition comprises about 200 mM of a polar excipient.

[0014] In some embodiments, the pharmaceutical composition comprises about 1% (w / v) to about 10% (w / v) (e.g., about 2% (w / v) to about 8% (w / v), e.g., about 1% (w / v), 1.5% (w / v), 2% (w / v), 2.5% (w / v), 3% (w / v), 3.5% (w / v), 4% (w / v), 4.5% (w / v), 5% (w / v), 5.5% (w / v), 6% (w / v), 6.5% (w / v), 7% (w / v), 7.5% (w / v), 8% (w / v), 8.5% (w / v), 9% (w / v), 9.5% (w / v), 10% (w / v)) of a polar excipient. In some embodiments, the pharmaceutical composition comprises about 2.5% (w / v) polar excipient. In some embodiments, the pharmaceutical composition comprises about 7% (w / v) polar excipient.

[0015] In some embodiments, the pharmaceutical composition comprises about 0.001% to about 0.1% (e.g., about 0.005% to 0.05%, e.g., about 0.001%, 0.002%, 0.003%, 0.004%, 0.005%, 0.006%, 0.007%, 0.008%, 0.009%, 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, or 0.1%) polysorbate 20. In some embodiments, the pharmaceutical composition comprises about 0.01% polysorbate 20. In some embodiments, the pharmaceutical composition comprises about 0.02% polysorbate 20.

[0016] The composition may have a pH of about 5.0 to about 8.0, such as about 5.4 to about 6.5, such as about 5.4 to about 5.75, such as 5.4 to about 5.6, such as 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9 and 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9 and 8.0, such as about 5.4.

[0017] In some embodiments, the pharmaceutical composition comprises about 50 mM sodium acetate, about 100 mM arginine, 100 mM glutamate, and about 0.02% polysorbate 20, and has a pH of about 5.4. In some embodiments, the pharmaceutical composition comprises about 50 mM acetate, about 50 mM arginine, 50 mM glutamate, and about 0.01% polysorbate 20. In some embodiments, the pharmaceutical composition comprises about 50 mM acetate, about 50 mM arginine, 50 mM glutamate, and about 0.02% polysorbate 20. In some embodiments, the pharmaceutical composition comprises about 50 mM acetate, about 100 mM arginine, 50 mM glutamate, and about 0.01% polysorbate 20. In some embodiments, the pharmaceutical composition comprises about 50 mM acetate, about 100 mM arginine, 50 mM glutamate, and about 0.02% polysorbate 20.

[0018] In some embodiments, the composition is administered intravenously or subcutaneously or by infusion. For example, the antibody or antigen-binding fragment thereof may be administered intravenously at a dose of about 1 mg / kg, 1.5 mg / kg, 2 mg / kg, 2.5 mg / kg, 3 mg / kg, 3.5 mg / kg, 4 mg / kg, 4.5 mg / kg, 5 mg / kg, 6 mg / kg, 7 mg / kg, 8 mg / kg, 9 mg / kg, 10 mg / kg, 11 mg / kg, 12 mg / kg, 13 mg / kg, 14 mg / kg, 15 mg / kg, 16 mg / kg, 17 mg / kg, 18 mg / kg, 19 mg / kg, or 20 mg / kg. In another example, the antibody or antigen-binding fragment thereof may be administered subcutaneously at a dosage of about 1 mg / kg, 1.5 mg / kg, 2 mg / kg, 2.5 mg / kg, 3 mg / kg, 3.5 mg / kg, 4 mg / kg, 4.5 mg / kg, 5 mg / kg, 6 mg / kg, 7 mg / kg, 8 mg / kg, 9 mg / kg, 10 mg / kg, 11 mg / kg, 12 mg / kg, 13 mg / kg, 14 mg / kg, 15 mg / kg, 16 mg / kg, 17 mg / kg, 18 mg / kg, 19 mg / kg, or 20 mg / kg.

[0019] The composition may be administered, for example, once a day, once a week, once every two weeks, once every three weeks, once a month, or once a year.In some embodiments, the composition is administered for at least one day, one week, two weeks, three weeks, one month, two months, three months, four months, five months, six months, one year, or more, for example, during the treatment regimen for the life of the subject.In one embodiment, the composition is administered to the subject until clinical remission is achieved or the lowest disease activity is achieved.

[0020] In some embodiments, the antibody or antigen-binding fragment thereof is administered subcutaneously at a concentration of about 2 mg / kg, 5 mg / kg, or 10 mg / kg once every two weeks. Alternatively, the antibody or antigen-binding fragment thereof is administered subcutaneously at a concentration of about 2 mg / kg, 5 mg / kg, or 10 mg / kg once every three or four weeks. For example, the composition may be administered for a treatment regimen of about 12 weeks or more (e.g., 6 months, 1 year, 2 years, 3 years, 4 years, 5 years, 6 years, or more, e.g., for the life expectancy of the subject).

[0021] The method may further include administration of an immunosuppressant, a disease-modifying antirheumatic drug (DMARD), or a Janus kinase (JA) inhibitor, for example within 6 months of administration of the antibody or antigen-binding fragment thereof.

[0022] In some embodiments, the antibody or antigen-binding fragment thereof is administered to a subject with active rheumatoid arthritis. In certain embodiments, the antibody or antigen-binding fragment thereof is administered to a subject with active rheumatoid arthritis who has an inadequate response (IR) to a JAK inhibitor (JAKi) or at least one disease-modifying antirheumatic drug (DMARD) or is intolerant to a JAK inhibitor (JAKi) or at least one disease-modifying antirheumatic drug (DMARD). In one embodiment, the DMARD is a conventional synthetic DMARD (csDMARD) (e.g., methotrexate, sulfasalazine, hydroxychloroquine, and leflunomide). In another embodiment, the DMARD is a biological DMARD (bDMARD; e.g., etanercept; adalimumab, infliximab, certolizumab, golimumab, abatacept, tocilizumab, sarilumab, and rituximab). In some embodiments, the subject is classified as an ACR RA functional class 1-3.

[0023] Immunosuppressants include calcineurin inhibitors, tacrolimus, mTor inhibitors, fingolimod, myriocin, alemtuzumab, rituximab, anti-CD4 monoclonal antibodies, anti-LFA1 monoclonal antibodies, anti-LFA3 monoclonal antibodies, anti-CD45 antibodies, anti-CD19 antibodies, monabatacept, belatacept, indolyl ASC; The agent may be selected from the group consisting of azathioprine, lymphocyte immunoglobulin and antithymocyte globulin [horse], mycophenolate mofetil, mycophenolate sodium, daclizumab, basiliximab, cyclophosphamide, prednisone, prednisolone, leflunomide, FK778, FK779, 15-deoxyspergualin, busulfan, fludarabine, methotrexate, 6-mercaptopurine, 15-deoxyspergualin, LF15-0195, bredinin, brequinar, and muromonab-CD3. In some embodiments, the calcineurin inhibitor is cyclosporine A or cyclosporine G, the mTor inhibitor is sirolimus, temsirolimus, zotarolimus, or everolimus, the anti-CD45 antibody is an anti-CD45RB antibody, or the immunosuppressant is belatacept. The antibody or antigen-binding fragment thereof and the immunosuppressant may be administered within one month or one week apart.

[0024] The JAK inhibitor may be, for example, ruxolitinib, tofacitinib, oclacitinib, baricitinib, peficitinib, fedratinib, upadacitinib, filgotinib, or delgocitinib.

[0025] The DMARD may be, for example, abatacept, adalimumab, anakinra, apremilast, azathioprine, baricitinib, certolizumab pegol, chloroquine, cyclosporine (cyclosporine A), D-penicillamine, etanercept, filgotinib, golimumab, gold salts (e.g., gold sodium thiomalate or auranofin), hydroxychloroquine, infliximab, leflunomide, methotrexate, minocycline, rituximab, sarilumab, secukinumab, sulfasalazine, tocilizumab, tofacitinib, or ustekinumab.

[0026] In some embodiments, the DMARD is a conventional synthetic DMARD.

[0027] In some embodiments, the subject has had an inadequate response to or is intolerant to a JAK inhibitor or DMARD.

[0028] In some embodiments, the method suppresses or reduces one or more symptoms associated with RA (e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%). One or more symptoms associated with RA can include, for example, inflamed (e.g., chronically inflamed) joints, cardiovascular disease, osteoporosis, interstitial lung disease, infection, cancer, fatigue, depression, mental difficulties, work difficulties, synovial inflammation, pain, finger deformity, osteoarthritis, ulnar deviation, boutonnier deformity, swan-neck deformity, thumb Z-shaped deformity (e.g., interphalangeal joint hyperextension, metacarpophalangeal joint flexion contracture and subluxation), hammer toe, and destructive arthritis. The suppression or reduction of symptoms can be measured relative to a control group (e.g., subjects who have not undergone the treatment regimen described herein) or relative to the baseline of the subject established, for example, before or after previous treatment with a different treatment regimen. Relief can include a decrease in the frequency and / or intensity of symptoms.

[0029] In one embodiment, the method includes using efficacy indicators such as Disease Activity Score in 28 Joints (DAS28) or DAS28-C Reactive Protein (DAS28-CRP) to monitor the efficacy of treatment in a subject with RA. If the DAS28 score is <2.6, the subject may be determined to be in remission. A DAS28 score of 3.2 or less may indicate that the subject is in remission or has moderate or low disease activity, and thus may require a reduced dosage of the therapeutic compositions described herein (e.g., less than 10 mg / kg per dose), a reduced frequency of administration (e.g., a dose of the therapeutic composition is administered once a week, once every two weeks, once every three weeks, or once every four weeks, or, as needed, to promote relief of symptoms present during an acute exacerbation or chronic symptoms), or both. If the DAS28 score is between 3.2 and 5.1, the subject may exhibit moderate or severe disease activity. Treatment of moderate or severe disease activity may require administration of a therapeutic composition described herein in a single dose of about 10 mg / kg or more per dose (e.g., about 20 mg / kg per dose), which may alternatively or additionally be administered more frequently, such as, for example, more than once per week or 2-5 times per 2-4 weeks, or until the subject experiences a decrease in RA symptoms (e.g., until the subject achieves a DAS28 score of <3.2).

[0030] In another embodiment, the efficacy index used to evaluate the efficacy of treatment is the American College of Rheumatology (ACR) 20 / 50 / 70 rating. ACR20 is a composite measure defined as a 20% improvement in the number of tender and swollen joints and a 20% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional capacity scale (the most frequently used Health Assessment Questionnaire (HAQ)), visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP). The ACR50 and ACR70 indices correspond to 50% and 70% improvement, respectively. The aforementioned evaluations can be used to guide dosing strategies, for example, when a subject requires an increase or decrease in the dosage or frequency of administration of an antibody or antigen-binding fragment thereof in response to a particular efficacy index (e.g., similar to the changes in the dosing regimen described above with the DAS28 index). For example, if the subject does not exhibit an ACR20, ACR50, or ACR70 score indicative of improvement in the measure tested, the dosage of a therapeutic composition described herein administered to the subject may be increased (e.g., greater than 10 mg / kg per dose (e.g., 20 mg / kg per dose)), the frequency of administration may be increased (e.g., more than once per week or 2-5 times for 2-4 weeks, or until the subject's symptoms of RA are reduced), or both may be increased. Alternatively, if the subject exhibits an ACR20, ACR50, or ACR70 score indicative of improvement in the measure tested, the dosage of a therapeutic composition described herein administered to the subject may be decreased (as discussed above), the frequency of administration of the composition may be decreased, or both may be decreased.

[0031] The methods described herein may include a treatment regimen that includes two treatment phases. For example, the treatment regimen may include an acute phase of treatment, including, for example, increasing the dosage, increasing the frequency of administration, or both, of the antibody or antigen-binding fragment thereof. The acute phase of treatment may include, for example, administering the antibody or antigen-binding fragment thereof intravenously or subcutaneously at a dosage of, for example, about 5 mg / kg to about 10 mg / kg (e.g., about 5 mg / kg, 6 mg / kg, 7 mg / kg, 8 mg / kg, 9 mg / kg, or 10 mg / kg), for example, once every two weeks, once a week, or twice a week, or more. The subject may then be monitored for a reduction (e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%) in one or more symptoms associated with RA. Suppression or alleviation of symptoms can be measured against a control group (e.g., a healthy subject or a different subject with RA who has not undergone the treatment regimen described herein) or against a subject prior to acute treatment. Alleviation can include, for example, a reduction in the frequency and / or intensity of symptoms measured by the assessment described herein. The reduction in frequency and / or amount of antibody or antigen-binding fragment thereof can be determined based on the efficacy indicators described herein (e.g., DAS28, DAS28 CRP, or ACR20 / 50 / 70 assessment). For example, if a subject achieves a DAS28 score of <3.2, it can be determined that the subject requires a reduction in the frequency or dosage of antibody or antigen-binding fragment thereof.

[0032] After acute treatment, e.g., treatment resulting in relief of one or more symptoms of RA or a reduction in DAS28 score (e.g., less than 2.6 or less than 3.2), the subject may then transition to a long-term administration regimen, including, for example, a reduction in the dosage of the antibody or antigen-binding fragment thereof, a reduction in the frequency of administration, or both, relative to the acute treatment. For example, chronic treatment may include intravenous or subcutaneous administration of the antibody or antigen-binding fragment thereof, e.g., once every 4 weeks, once every 2 weeks, or once a week, at a dosage of, e.g., about 1 mg / kg to about 5 mg / kg (e.g., about 1 mg / kg, 1.5 mg / kg, 2 mg / kg, 2.5 mg / kg, 3 mg / kg, 3.5 mg / kg, 4 mg / kg, 4.5 mg / kg, or 5 mg / kg). Such a long-term administration regimen may reduce the overall dosage administered to the subject while still maintaining therapeutic efficacy.

[0033] A subject may be transitioned from acute to chronic dosing (e.g., if a relief is observed in one or more RA symptoms) or from chronic to acute dosing (e.g., if a worsening of one or more RA symptoms is observed) one or more times during treatment with an anti-CD40 antibody or antigen-binding fragment thereof, as appropriate, for example, based on RA symptoms observed in the subject.

[0034] In certain embodiments, the subject is identified as a responder to treatment with an anti-CD40 antibody or antigen-binding fragment thereof and as having a statistically significant improvement in disease activity, where disease activity is determined by one or more criteria selected from the group consisting of ACR20, ACR50, ACR70, DAS28, DAS28-CRP, Physician Global Assessment of Disease Activity (PhGA), Health Assessment Questionnaire-Disability Index (HAQ-DI), Short Form Health Survey (SF-36) in Physical Health Composite Score (PCS) and Mental Health Composite Score (MCS), SF-36 Total Composite Score (TCS), Clinical Disease Activity Index (CDAI), SDAI (calculated from CDAI+DAS28-CRP), and visual analog scale (VAS) for pain. In certain embodiments, the subject achieves a significant improvement in ACR20 response to KPL-404 versus placebo by week 12 of treatment. In another embodiment, the subject achieves a significant improvement in ACR20 response to KPL-404 vs. placebo by week 24 of treatment. In one embodiment, the subject achieves a significant improvement in ACR20 response to KPL-404 vs. placebo by week 52 of treatment. In a particular embodiment, the subject achieves a significant improvement in ACR50 response to KPL-404 vs. placebo by week 12 of treatment. In another embodiment, the subject achieves a significant improvement in ACR50 response to KPL-404 vs. placebo by week 24 of treatment. In one embodiment, the subject achieves a significant improvement in ACR50 response to KPL-404 vs. placebo by week 52 of treatment.

[0035] In some embodiments, a 20% improvement in the American College of Rheumatology Core Set Disease Index (ACR20) is achieved following treatment.

[0036] In some embodiments, a 50% improvement in the American College of Rheumatology Core Set Disease Index (ACR50) is achieved following treatment.

[0037] In some embodiments, ACR20 is achieved after about 1 week of treatment regimen. In some embodiments, ACR20 is achieved after about 24 weeks of treatment regimen. In some embodiments, ACR20 is achieved after about 52 weeks of treatment regimen. In some embodiments, ACR20 is achieved after about 1 week to about 52 weeks of treatment regimen.

[0038] In some embodiments, ACR50 is achieved after about 12 weeks of treatment regimen. In some embodiments, ACR50 is achieved after about 24 weeks of treatment regimen. In some embodiments, ACR50 is achieved after about 52 weeks of treatment regimen. In some embodiments, ACR50 is achieved after about 12 weeks to about 52 weeks of treatment regimen.

[0039] In some embodiments, a Disease Activity Score of 28 joints using C-reactive protein (DAS28-CRP) is achieved following treatment. In some embodiments, the DAS28-CRP is achieved after about 12 weeks of a treatment regimen. In some embodiments, the DAS28-CRP is achieved after about 24 weeks of a treatment regimen. In some embodiments, the DAS28-CRP is achieved after about 52 weeks of a treatment regimen. In some embodiments, the DAS28-CRP is achieved after about 12 weeks to about 52 weeks of a treatment regimen.

[0040] In some embodiments, after treatment, the subject can achieve an improvement in disease activity as determined by a measure selected from the group consisting of ACR20, ACR50, ACR70, DAS28, DAS28-CRP, Physician Global Assessment of Disease Activity (PhGA), Health Assessment Questionnaire-Disability Index (HAQ-DI), Short Form Health Survey (SF-36) in the Physical Health Composite Score (PCS) and Mental Health Composite Score (MCS), SF-36 Total Composite Score (TCS), Clinical Disease Activity Index (CDAI), Simple Disease Activity Index (SDAI), and Visual Analog Scale (VAS) for Pain, and combinations thereof.

[0041] definition As used herein, the term "about" means ±10% of the recited value. [Brief description of the drawings]

[0042] [Figure 1] FIG. 1 is a schematic diagram showing the overall scheme of a clinical study involving administration of a pharmaceutical composition of the present disclosure. [Diagram 2] FIG. 2 is a schematic diagram showing a clinical trial scheme for administration of the pharmaceutical compositions of the present disclosure. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0043] The present disclosure features a method of treating, alleviating, or suppressing rheumatoid arthritis in a subject in need thereof by administering a pharmaceutical composition containing an anti-CD40 antibody or antigen-binding fragment thereof in an amount of about 1 mg / kg to about 10 mg / kg (e.g., about 2 mg / kg, 5 mg / kg, or 10 mg / kg). The pharmaceutical composition contains an anti-CD40 antibody or antigen-binding fragment thereof that can block the ability of CD40 to bind to CD154, and can do so without activating cells (e.g., B cells) that express CD40. Anti-CD40 therapy can also attenuate T cell function, such as T cell cytotoxicity (e.g., via CD40 blockade on antigen-presenting cells), which can be a therapeutic agent for rheumatoid arthritis, particularly in subjects who experience an inadequate response to or are intolerant to a JAK inhibitor (JAKi) or at least one disease-modifying antirheumatic drug (DMARD).

[0044] Generally, the antibody or antigen-binding fragment thereof is derived from the murine 2C10 antibody and its humanized variants, for example, as described in PCT Publications WO2012 / 125569 and WO2017 / 040932, which are incorporated by reference in their entireties. The methods and pharmaceutical compositions used in said patent documents are described in more detail below.

[0045] Antibodies and antigen-binding fragments thereof The methods described herein include, for example, administration of an antibody or antigen-binding fragment thereof derived from the murine 2C10 antibody. The heavy chain variable region, light chain variable region, and CDRs of certain anti-CD40 antibodies described herein are shown in Table 1. [Table 1-1] [Table 1-2] [Table 1-3]

[0046] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, about 70%, about 75%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% identical to the amino acid sequence of the heavy chain variable region set forth in SEQ ID NO:9.

[0047] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region comprising an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, about 70%, about 75%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% identical to the amino acid sequence of the light chain variable region set forth in SEQ ID NO:10.

[0048] In certain embodiments, the antibody or antigen-binding fragment thereof comprises an antibody having an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, about 70%, about 75%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% identical to the amino acid sequence of the heavy chain variable region set forth in SEQ ID NO:9. and a light chain variable region comprising an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, about 70%, about 75%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% identical to the variable light chain amino acid sequence set forth in SEQ ID NO:10.

[0049] In certain embodiments, the antibody or antigen-binding fragment thereof comprises an antibody having an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, about 70%, about 75%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% identical to a heavy chain having an amino acid sequence set forth in SEQ ID NO:11. and a light chain region comprising an amino acid sequence that is at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, about 70%, about 75%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% identical to the light chain amino acid sequence set forth in SEQ ID NO:12.

[0050] In certain embodiments, the antibody or antigen-binding fragment thereof has an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, about 70%, about 75%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% sequence identity to the amino acid sequence of a heavy chain variable region set forth in any one of SEQ ID NOs: 13, 14, 16, 17 or 18. and a light chain variable region comprising an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, about 70%, about 75%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% sequence identity to the variable light chain amino acid sequence set forth in any one of SEQ ID NOs: 15, 19, 20 or 21.

[0051] In certain embodiments, the heavy chain variable region of the antibody or antigen-binding fragment thereof comprises complementarity determining regions (CDRs) that are at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, about 70%, about 75%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% identical to the CDRs of the heavy chain variable region of the KPL-404 antibody (CDR1, CDR2 and CDR3 set forth in SEQ ID NOs: 3, 4, 5, respectively).

[0052] In certain embodiments, the light chain variable region of the antibody or antigen-binding fragment thereof comprises CDRs that are at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, about 70%, about 75%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% identical to the CDRs of the light chain variable region of the KPL-404 antibody (CDR1, CDR2 and CDR3 set forth in SEQ ID NOs: 6, 7, 8, respectively).

[0053] In certain embodiments, the heavy chain comprises the CDRs set forth in SEQ ID NOs: 3-5, respectively, and the light chain comprises the CDRs set forth in SEQ ID NOs: 6-8, respectively.

[0054] In certain embodiments, the heavy chain has at least 80% (e.g., at least 85%, 90%, 95%, 97%, 99%, or 100%) sequence identity to SEQ ID NO:9 and the CDRs set forth in SEQ ID NOs:3-5, respectively, and the light chain has at least 80% (e.g., at least 85%, 90%, 95%, 97%, 99%, or 100%) sequence identity to SEQ ID NO:10 and the CDRs set forth in SEQ ID NOs:6-8, respectively.

[0055] Also within the scope of the present disclosure are antibodies or antigen-binding fragments in which specific amino acids are substituted, deleted, or added. These changes have no substantial effect on the biological properties of the peptide, such as binding activity. For example, an antibody may have amino acid substitutions in the framework region, such as to improve binding to an antigen. In another example, a selected small number of acceptor framework residues may be replaced by the corresponding donor amino acids. The donor framework may be a mature or germline human antibody framework sequence or a consensus sequence. Guidance on how to make phenotypically silent amino acid substitutions can be found, for example, in Bowie et al. (Science, 247: 1306-1310, 1990), Cunningham et al. (Science, 244: 1081-1085, 1989), Ausubel (ed.) (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., 1994), T. Maniatis, E. F. Fritsch and J. Sambrook (Molecular Cloning: A Laboratory Manual, Cold Spring Harbor laboratory, Cold Spring Harbor, NY, 1989), Pearson (Methods Mol. Biol. 243:307-31, 1994), and Gonnet et al. (Science 256:1443-45, 1992), each of which is incorporated herein by reference.

[0056] The polypeptides described herein may be functionally active variants of the antibodies or antigen-binding fragments thereof disclosed herein, e.g., having less than about 30%, about 25%, about 20%, about 15%, about 10%, about 5% or about 1% of the amino acid residues substituted or deleted, but having essentially the same immunological properties (including, but not limited to, binding to CD40).

[0057] In some embodiments, the dissociation constant (K D ) is approximately 1 × 10 -8 Less than, for example, about 1 x 10 -9 is less than.

[0058] An antibody or antigen-binding fragment thereof may also contain one or more analogs of amino acids (including, for example, unnatural amino acids, amino acids that occur naturally only in unrelated biological systems, modified amino acids from mammalian systems, etc.), polypeptides with substituted bonds, as well as other modifications known in the art.

[0059] Indications The methods described herein include administering a pharmaceutical composition containing an antibody or antigen-binding fragment described herein to a subject having rheumatoid arthritis in an in vivo protocol (e.g., therapeutic or prophylactic) for the treatment of rheumatoid arthritis or to reduce, inhibit, or alleviate one or more symptoms of rheumatoid arthritis. An anti-CD40 antibody or antigen-binding fragment thereof can be administered to treat rheumatoid arthritis or to treat or reduce the likelihood of developing one or more symptoms of rheumatoid arthritis.

[0060] Rheumatoid arthritis (RA) is a long-term autoimmune disease that mainly affects joints, but can also affect other organs.RA is most often characterized by inflamed (e.g., chronically inflamed) joints.RA can also include or be associated with other secondary problems, including cardiovascular disease, osteoporosis, interstitial lung disease, infection, cancer, fatigue, depression, mental difficulties, and work difficulties.

[0061] RA of joints is accompanied by inflammation of synovium.Symptoms include, for example, swelling, tenderness, warmth, and stiffness and associated pain of joints.Digital may suffer from deformity depending on which joints are involved, often resulting in osteoarthritis, ulnar deviation, boutonnier deformity, swan-neck deformity, Z-shaped thumb deformity (e.g., hyperextension of interphalangeal joints, flexion contracture and subluxation of metacarpophalangeal joints), hammer toe, and destructive arthritis.

[0062] Cutaneous RA can result in an inflammatory response known as necrotizing granulomas, which result in the formation of nodules containing a central area of ​​fibrinoid necrosis that can tear around the affected synovial cavity. Other skin problems include vasculitis, pyoderma gangrenosum, Sweet's syndrome, drug reactions, erythema nodosum, lobular panniculitis, digital skin atrophy, palmar erythema, and skin fragility, as well as generalized alopecia areata.

[0063] Other sequelae associated with RA include, for example, pulmonary fibrosis, exudative pleural effusion, atherosclerosis, myocardial infarction and stroke, pericarditis, endocarditis, left ventricular failure, valvular inflammation, fibrosis, anemia, renal amyloidosis, episcleritis, scleritis, keratoconjunctivitis sicca, keratitis, peripheral neuropathy, mononeuritis multiplex, carpal tunnel syndrome, atlantoaxial subluxation, focal osteoporosis, lymphoma, and periodontitis.

[0064] Subjects with RA can be classified based on the severity of disease prevalence. For example, subjects can be stratified according to the number of affected joints (e.g., 1 large joint, 2-10 large joints, 1-3 small joints, 4-10 small joints, or 10 or more joints).

[0065] In some embodiments, subjects with RA who exhibit persistent signs and symptoms, drug resistance, and who have failed to respond to two or more biologic therapies and have failed to respond to anti-rheumatic drugs with different mechanisms of action may be classified as difficult to treat (D2T RA).

[0066] In some embodiments, the subject is classified as an ACR RA functional class 1-3 using the 2010 American College of Rheumatology (ACR) / European League Against Rheumatism (EULAR) classification criteria for RA.

[0067] Standard treatment includes early treatment with disease-modifying antirheumatic drugs (DMARDs), including conventional synthetic DMARDs (csDMARDs) (e.g., methotrexate, sulfasalazine, hydroxychloroquine, and leflunomide). Targeted biological DMARDs (bDMARDs) advance the treatment paradigm for RA, where treatment is optimized until clinical remission or minimal disease activity is achieved. However, despite the broad therapeutic armamentarium of bDMARDs, blockade of any single cytokine or cell subset has not demonstrated disease control in all RA subjects. In some embodiments, an antibody or antigen-binding fragment thereof is administered to a subject with active rheumatoid arthritis. In certain embodiments, the antibody or antigen-binding fragment thereof is administered to a subject with active rheumatoid arthritis who has an inadequate response to a JAK inhibitor (JAKi-IR) or at least one disease-modifying antirheumatic drug (DMARD-IR) or is intolerant to a JAK inhibitor (JAKi-IR) or at least one disease-modifying antirheumatic drug (DMARD-IR). In one embodiment, the DMARD is a conventional synthetic DMARD (csDMARD) (e.g., methotrexate, sulfasalazine, hydroxychloroquine, and leflunomide). In another embodiment, the DMARD is a biological DMARD (e.g., etanercept, adalimumab, infliximab, certolizumab, golimumab, abatacept, tocilizumab, and rituximab).

[0068] In some embodiments, the subject has had an inadequate response to or is intolerant to a JAK inhibitor or DMARD.

[0069] The methods described herein can be used to treat RA, or to reduce the onset or severity of, for example, one or more symptoms or associated sequelae of RA described herein, compared to subjects who are not treated with anti-CD40 antibody or antigen-binding fragment thereof.For example, the methods can reduce the length of time that a subject experiences one or more symptoms or associated sequelae of RA (e.g., by one or more days, one or more weeks, or one or more months).The methods described herein can be used to treat RA of any classification or severity described herein (e.g., D2T RA).

[0070] The methods described herein can suppress or reduce one or more symptoms associated with RA (e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%). The suppression or reduction of symptoms can be measured against a control group (e.g., a healthy subject or a different subject with RA who does not receive the treatment regimen described herein), or against a subject before or after prior treatment with, for example, a different treatment regimen, e.g., a failed treatment regimen. The reduction can include a reduction in the frequency and / or intensity of symptoms.

[0071] The methods described herein can be used in combination with immunosuppression (eg, by co-administration with an immunosuppressant).

[0072] Pharmaceutical Compositions The present invention features a method of treating, alleviating, or suppressing rheumatoid arthritis as described herein in a subject in need thereof by administering a pharmaceutical composition containing an antibody or antigen-binding fragment thereof described herein (e.g., an antibody or antigen-binding fragment thereof containing a heavy chain variable region having at least 80%, 85%, 90%, 95%, 97%, 99%, or 100% sequence identity to SEQ ID NO: 9 and a light chain variable region having at least 80%, 85%, 90%, 95%, 97%, 99%, or 100% sequence identity to SEQ ID NO: 10, formulated with a pharma- ceutically acceptable carrier). The antibody or antigen-binding fragment thereof may be formulated in the pharmaceutical composition at a concentration of about 50 to about 300 mg / mL and optionally at a volume of about 0.5 mL to about 2.0 mL (e.g., about 1.0 mL). The compositions can be administered to a subject prior to the onset of symptoms of RA, prior to a diagnosis of RA (e.g., a subject susceptible to developing RA), or after the onset of one or more symptoms of RA or after a diagnosis of RA.

[0073] The antibody or antigen-binding fragment thereof (e.g., KPL-404) may be incorporated into a pharmaceutical composition (e.g., at a concentration of about 50 mg / mL to about 300 mg / mL, such as about 100 mg / mL or about 200 mg / mL), polysorbate 20, acetate, and one or more polar excipients. The polar excipient may be or may include, for example, a sugar, a polyol, or an amino acid. In some embodiments, the sugar is, for example, sucrose, trehalose, fructose, lactose, dextrose, or mannitol. In some embodiments, the polyol is, for example, polyethylene glycol or sorbitol. In some embodiments, the amino acid is one or more of alanine, arginine, aspartic acid, asparagine, carnitine, citrulline, ornithine, glycine, glutamic acid, glutamine, glycine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tyrosine, and valine. Acetate may include, for example, sodium acetate (e.g., in salt form) or acetate ions in its ionic form. In some embodiments, the antibody or antigen-binding fragment. In some embodiments, the polar excipient is, for example, sucrose, arginine, glutamate, sorbitol, or a combination thereof. In some embodiments, the polar excipient is sucrose. In some embodiments, the polar excipient is arginine. In some embodiments, the polar excipient is glutamate. In some embodiments, the polar excipient is a mixture of arginine and glutamate. In some embodiments, the polar excipient is sorbitol.

[0074] The pharmaceutical composition may contain about 5 mM to about 100 mM (e.g., about 10 mM to about 90 mM, for example, about 25 mM to about 75 mM, for example, about 40 mM to about 60 mM, for example, about 45 mM to about 55 mM, for example, about 5 mM, 10 mM, 20 mM, 30 mM, 40 mM, 50 mM, 60 mM, 70 mM, 80 mM, 90 mM, or 100 mM, for example, about 50 mM acetate, about 1 mM to about 200 mM (e.g., about 50 mM to about 150 mM, for example, about 75 mM to about 125 mM, For example, about 90 mM to about 110 mM, for example, about 95 mM to about 105 mM, for example, about 1 mM, 2 mM, 3 mM, 4 mM, 5 mM, 10 mM, 20 mM, 30 mM, 40 mM, 50 mM, 60 mM, 70 mM, 80 mM, 90 mM, 100 mM, 110 mM, 120 mM, 130 mM, 140 mM, 150 mM, 160 mM, 170 mM, 180 mM, 190 mM, or 200 mM, for example, about 100 mM), or about 1% (w / v) to about 10% (w / v) (e.g. For example, about 2% (w / v) to about 8% (w / v), for example, about 1% (w / v), 1.5% (w / v), 2% (w / v), 2.5% (w / v), 3% (w / v), 3.5% (w / v), 4% (w / v), 4.5% (w / v), 5% (w / v), 5.5% (w / v), 6% (w / v), 6.5% (w / v), 7% (w / v), 7.5% (w / v), 8% (w / v), 8.5% (w / v), 9% (w / v), 9.5% (w / v), 10% (w / v), for example, about 2.5% (w The formulation may comprise about 7% (w / v) or about 7% (w / v) of a polar excipient, and about 0.001% to about 0.1% (e.g., 0.001%, about 0.002%, 0.003%, 0.004%, 0.005%, 0.006%, 0.007%, 0.008%, 0.009%, 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, or 0.1%, e.g., about 0.01% or about 0.02%) of polysorbate 20.The pharmaceutical composition may have a pH of about 5.0 to about 8.0, for example, about 5.4 to about 6.5, for example, about 5.4 to about 5.75, for example, 5.4 to about 5.6, for example, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9 and 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9 and 8.0. For example, the pH may be about 5.4.

[0075] In some embodiments, the antibody or antigen-binding fragment (e.g., KPL-404) may be incorporated into a pharmaceutical composition (e.g., at a concentration of about 50 mg / mL to about 300 mg / mL, e.g., about 100 mg / mL or about 200 mg / mL) containing 50 mM acetate, 100 mM arginine, 100 mM glutamate, and 0.01% polysorbate 20 and having a pH of 5.4. The antibody or antigen-binding fragment (e.g., KPL-404) may be incorporated into a pharmaceutical composition (e.g., at a concentration of about 50 mg / mL to about 300 mg / mL, e.g., about 100 mg / mL or about 200 mg / mL) containing 50 mM acetate, 100 mM arginine, 100 mM glutamate, and 0.02% polysorbate 20 and having a pH of 5.4. The pharmaceutical composition of the present disclosure may also be modified in its formulation. For example, the pharmaceutical composition may contain polysorbate 20, sodium acetate, arginine, and glutamate in amounts different from those described above. For example, the pharmaceutical composition may contain about 5 mM to about 100 mM (e.g., about 10 mM, 20 mM, 30 mM, 40 mM, 50 mM, 60 mM, 70 mM, 80 mM, 90 mM, or 100 mM) of sodium acetate, for example, about 50 mM of sodium acetate. The pharmaceutical composition can include about 1 mM to about 200 mM (e.g., about 1 mM, 2 mM, 3 mM, 4 mM, 5 mM, 10 mM, 20 mM, 30 mM, 40 mM, 50 mM, 60 mM, 70 mM, 80 mM, 90 mM, 100 mM, 110 mM, 120 mM, 130 mM, 140 mM, 150 mM, 160 mM, 170 mM, 180 mM, 190 mM, or 200 mM) arginine, for example about 100 mM arginine. The pharmaceutical composition can include about 1 mM to about 200 mM (e.g., about 1 mM, 2 mM, 3 mM, 4 mM, 5 mM, 10 mM, 20 mM, 30 mM, 40 mM, 50 mM, 60 mM, 70 mM, 80 mM, 90 mM, 100 mM, 110 mM, 120 mM, 130 mM, 140 mM, 150 mM, 160 mM, 170 mM, 180 mM, 190 mM, or 200 mM) glutamate, for example about 100 mM glutamate.The pharmaceutical composition can include about 0.001% to about 0.1% (e.g., 0.002%, 0.003%, 0.004%, 0.005%, 0.006%, 0.007%, 0.008%, 0.009%, 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, or 0.1%) polysorbate 20, such as about 0.02% polysorbate 20. In some embodiments, the pharmaceutical composition includes about 50 mM acetate, about 100 mM arginine, 100 mM glutamate, and about 0.02% polysorbate 20. In some embodiments, the pharmaceutical composition comprises about 50 mM acetate, about 50 mM arginine, 50 mM glutamate, and about 0.01% polysorbate 20. In some embodiments, the pharmaceutical composition comprises about 50 mM acetate, about 50 mM arginine, 50 mM glutamate, and about 0.02% polysorbate 20. In some embodiments, the pharmaceutical composition comprises about 50 mM acetate, about 100 mM arginine, 50 mM glutamate, and about 0.02% polysorbate 20. In some embodiments, the pharmaceutical composition comprises about 50 mM acetate, about 100 mM arginine, 50 mM glutamate, and about 0.02% polysorbate 20.

[0076] For example, the pharmaceutical composition may contain about 5 mM to about 100 mM (e.g., about 10 mM to about 90 mM, for example, about 25 mM to about 75 mM, for example, about 40 mM to about 60 mM, for example, about 45 mM to about 55 mM, for example, about 5 mM, 10 mM, 20 mM, 30 mM, 40 mM, 50 mM, 60 mM, 70 mM, 80 mM, 90 mM, or 100 mM, for example, about 50 mM) sodium acetate and about 1 mM to about 200 mM (e.g., about 50 mM to about 150 mM, for example, about 75 mM to about 125 mM, for example, about 90 mM to about 110 mM, for example, about 95 mM to about 105 mM, for example, about 1 mM, 2 mM, 3 mM, 4 mM, 5 mM, 10 mM, 20 mM, 30 mM, 40 mM, 50 mM, 60 mM, 70 mM, 80 mM, 90 mM, 100 mM, 110 mM, 120 mM, 130 mM, 140 mM, 150 mM, 160 mM, 170 mM, 180 mM, 190 mM, or 200 mM, for example, about 100 mM) arginine; About 1 mM to about 200 mM (for example, about 50 mM to about 150 mM, for example, about 75 mM to about 125 mM, for example, about 90 mM to about 110 mM, for example, about 95 mM to about 105 mM, for example, about 1 mM, 2 mM, 3 mM, 4 mM, 5 mM, 10 mM, 20 mM, 30 mM, 40 mM, 50 mM, 60 mM, 70 mM, 80 mM, 90 mM, 100 mM, 110 mM, 120 mM, 130 mM, 140 mM, 150 mM, 160 mM, 170 mM, 180 mM, The pharmaceutical composition may comprise 190 mM or 200 mM, e.g., about 100 mM) glutamate and about 0.001% to about 0.1% (e.g., 0.002%, 0.003%, 0.004%, 0.005%, 0.006%, 0.007%, 0.008%, 0.009%, 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, or 0.1%, e.g., about 0.02%) polysorbate 20. The pharmaceutical composition may have a pH of about 5.0 to about 6.0. For example, the pH may be about 5.4.

[0077] A pharmaceutical composition can contain an amount of an anti-CD40 antibody or antigen-binding fragment thereof described herein (eg, KPL-404) such as, for example, about 50 mg / mL to about 300 mg / mL.

[0078] The antibody or antigen-binding fragment thereof (e.g., KPL-404) may also be incorporated into a pharmaceutical composition containing about 50 mM acetate, about 7% (w / v) sucrose, and about 0.01% polysorbate 20 (e.g., at a concentration of about 100 mg / mL to about 300 mg / mL, such as 200 mg / mL), wherein the pharmaceutical composition has a pH of about 5.4.

[0079] The antibody or antigen-binding fragment thereof (e.g., KPL-404) may also be incorporated into a pharmaceutical composition containing about 50 mM acetate, about 2.5% (w / v) sorbitol, about 70 mM NaCl, and about 0.02% polysorbate 20 (e.g., at a concentration of about 50 mg / mL to about 300 mg / mL, such as about 100 mg / mL or about 200 mg / mL), wherein the pharmaceutical composition has a pH of about 5.4.

[0080] The antibody or antigen-binding fragment thereof may be provided in a container that contains the pharmaceutical composition described herein. Suitable containers include, for example, bottles, vials, syringes, and test tubes. The container may be formed from a variety of materials, such as glass or plastic. The container may hold, for example, a pharmaceutical composition described herein that is effective for treating a condition and may have a sterile access port. For example, the container may be an intravenous solution bag or vial with a stopper pierceable by a hypodermic injection needle. A label on or attached to the container indicates that the composition is used to treat a selected condition. The kit may further include a second container with a pharma- ceutically acceptable buffer, such as phosphate buffered saline, Ringer's solution, and dextrose solution. The kit may further include other items desirable from a commercial and user standpoint, such as other buffers, diluents, filters, needles, syringes, and package inserts with instructions for use.

[0081] The antibody or antigen-binding fragment thereof may be present in the container at a concentration of about 50 mg / mL to about 300 mg / mL (e.g., 100 mg / mL, 110 mg / mL, 120 mg / mL, 130 mg / mL, 140 mg / mL, 150 mg / mL, 160 mg / mL, 170 mg / mL, 180 mg / mL, 190 mg / mL, 200 mg / mL, 210 mg / mL, 220 mg / mL, 230 mg / mL, 240 mg / mL, 250 mg / mL, 260 mg / mL, 270 mg / mL, 280 mg / mL, 290 mg / mL, or 300 mg / mL), such as a concentration of about 100 mg / mL or about 200 mg / mL.

[0082] The composition may be formulated in a single-use vial with an extractable volume of about 1.0 mL or 2.0 mL. The composition may be formulated in a volume of about 0.1 mL to about 2.0 mL (e.g., 0.1 mL, 0.2 mL, 0.3 mL, 0.4 mL, 0.5 mL, 0.6 mL, 0.7 mL, 0.8 mL, 0.9 mL, 1.0 mL, 1.1 mL, 1.2 mL, 1.3 mL, 1.4 mL, 1.5 mL, 1.6 mL, 1.7 mL, 1.8 mL, 1.9 mL, or 2.0 mL), such as a volume of about 1.0 mL.

[0083] Route of Administration and Method of Treatment The compositions described herein can be administered by various methods known in the art. As will be appreciated by those skilled in the art, the route and / or mode of administration will vary depending on the desired results. Administration may be parenteral, intravenous, intrathecal, subcutaneous, oral, topical, local, intramuscular, intradermal, transdermal, subdermal, rectal, spinal, or epidermal. Intravenous delivery by continuous infusion is one exemplary method for administering the antibody or antigen-binding fragment thereof.

[0084] The compositions described herein may include a pharma- ceutically acceptable diluent, such as saline and aqueous buffer solutions.

[0085] Parenteral administration can include modes of administration other than enteral and topical administration, usually by injection, and can include, but are not limited to, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural, and intrasternal injection and infusion.

[0086] The methods described herein may include administering the pharmaceutical composition by injection, intravenously, or subcutaneously. The methods may include administering an antibody or antigen-binding fragment thereof at a dosage of about 1 mg / kg to about 20 mg / kg, e.g., about 1 mg / kg to about 10 mg / kg (e.g., about 2 mg / kg to about 10 mg / kg, e.g., about 1 mg / kg, 1.5 mg / kg, 2 mg / kg, 2.5 mg / kg, 3 mg / kg, 3.5 mg / kg, 4 mg / kg, 4.5 mg / kg, 5 mg / kg, 6 mg / kg, 7 mg / kg, 8 mg / kg, 9 mg / kg, 10 mg / kg, 11 mg / kg, 12 mg / kg, 13 mg / kg, 14 mg / kg, 15 mg / kg, 16 mg / kg, 17 mg / kg, 18 mg / kg, 19 mg / kg, or 20 mg / kg).

[0087] For example, the antibody or antigen-binding fragment thereof may be administered intravenously at a dosage of about 1 mg / kg, 1.5 mg / kg, 2 mg / kg, 2.5 mg / kg, 3 mg / kg, 3.5 mg / kg, 4 mg / kg, 4.5 mg / kg, 5 mg / kg, 6 mg / kg, 7 mg / kg, 8 mg / kg, 9 mg / kg, 10 mg / kg, 11 mg / kg, 12 mg / kg, 13 mg / kg, 14 mg / kg, 15 mg / kg, 16 mg / kg, 17 mg / kg, 18 mg / kg, 19 mg / kg, or 20 mg / kg.

[0088] In another example, the antibody or antigen-binding fragment thereof may be administered subcutaneously at a dosage of about 1 mg / kg, 1.5 mg / kg, 2 mg / kg, 2.5 mg / kg, 3 mg / kg, 3.5 mg / kg, 4 mg / kg, 4.5 mg / kg, 5 mg / kg, 6 mg / kg, 7 mg / kg, 8 mg / kg, 9 mg / kg, 10 mg / kg, 11 mg / kg, 12 mg / kg, 13 mg / kg, 14 mg / kg, 15 mg / kg, 16 mg / kg, 17 mg / kg, 18 mg / kg, 19 mg / kg, or 20 mg / kg.

[0089] The composition may be administered, for example, once a day, once a week, once every two weeks, once every three weeks, once a month, or once a year.In some embodiments, the composition is administered for at least one day, one week, two weeks, three weeks, one month, two months, three months, four months, five months, six months, one year, or more, for example, during the treatment regimen for the life expectancy of the subject.In one embodiment, the composition is administered to the subject until clinical remission is achieved or the lowest disease activity is achieved.

[0090] In one example, the antibody or antigen-binding fragment thereof is administered subcutaneously, e.g., once every two weeks, at a concentration of about 2 mg / kg, about 5 mg / kg, or about 10 mg / kg. For example, the composition may be administered for a treatment regimen of about 12 weeks or more, e.g., for the remainder of the subject's life.

[0091] The methods described herein may include using efficacy indicators such as Disease Activity Score in 28 Joints (DAS28) or DAS28-C Reactive Protein (DAS28-CRP), for example, as described in Hansen et al. J. Clin. Rheumatol. 23:102-106, 2017, which is incorporated herein by reference in its entirety. For example, DAS28 or DAS28-CRP scores can be used to monitor the efficacy of treatment of a subject with RA. If the DAS28 score is <2.6, the subject may be determined to be in remission. A DAS28 score of 3.2 or less may indicate that the subject is in remission or has moderate or low disease activity, and may therefore require a reduced dosage of the therapeutic compositions described herein (e.g., less than 10 mg / kg per dose, e.g., 5 mg / kg), a reduced frequency of administration (e.g., a single dose of the therapeutic composition may be administered once per week, once per two weeks, once per three weeks, or once per four weeks, or once every other month, or may be administered to promote relief of symptoms present during an acute exacerbation, or relief of chronic symptoms, as needed), or both. A DAS28 score of 3.2 to 5.1 may indicate moderate or severe disease activity. Treatment of moderate or severe disease activity may require administration of a therapeutic composition described herein at a single dose of about 10 mg / kg or more per dose (e.g., about 20 mg / kg per dose). Alternatively, or additionally, the dose may be administered more frequently, such as once or more than once weekly, once every two weeks, or 2-5 times every 2-4 weeks, or until the subject's symptoms of RA are reduced (e.g., until the subject achieves a DAS28 score of <3.2).

[0092] Another index that can be used to evaluate treatment efficacy is the American College of Rheumatology (ACR) 20 / 50 / 70 assessment. The 20% improvement in the American College of Rheumatology Core Set Disease Index (ACR20) is a composite measure defined as both a 20% improvement in the number of tender and swollen joints and a 20% improvement in three of the following five criteria: patient's global assessment, physician's global assessment, functional capacity scale (the most frequently used Health Assessment Questionnaire (HAQ)), visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP). The ACR50 and ACR70 indices correspond to a 50% and 70% improvement in the American College of Rheumatology Core Set Disease Index, respectively. These assessments are described, for example, in US2022 / 0025035, which is incorporated herein by reference in its entirety. The foregoing assessments can be used to guide dosing strategies, for example, if a subject requires an increase or decrease in the dosage or frequency of dosing of an antibody or antigen-binding fragment thereof in response to a particular efficacy indicator (e.g., similar to the changes in dosing regimens described above in conjunction with the DAS28 index).

[0093] The methods described herein may include a treatment regimen that includes two treatment phases. For example, the treatment regimen may include an acute phase of treatment, including, for example, increasing the dosage, increasing the frequency of administration, or both, of the antibody or antigen-binding fragment thereof. The acute phase of treatment may include, for example, administering the antibody or antigen-binding fragment thereof intravenously or subcutaneously at a dosage of, for example, about 5 mg / kg to about 10 mg / kg (e.g., about 5 mg / kg, 6 mg / kg, 7 mg / kg, 8 mg / kg, 9 mg / kg, or 10 mg / kg), for example, once every two weeks, once a week, or twice a week, or more. The subject may then be monitored for a reduction (e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% reduction) of one or more symptoms associated with RA. Suppression or alleviation of symptoms can be measured against a control group (e.g., a healthy subject or a different subject with RA who does not receive the treatment regimen described herein) or against a subject prior to acute treatment. Alleviation can include, for example, a reduction in the frequency and / or intensity of symptoms measured by the assessment described herein. The reduction in frequency and / or amount of antibody or antigen-binding fragment thereof can be determined based on the efficacy indicators described herein (e.g., DAS28, DAS28 CRP, or ACR20 / 50 / 70 assessment). For example, if a subject achieves a DAS28 score of <3.2, it can be determined that the subject requires a reduction in the frequency or dosage of antibody or antigen-binding fragment thereof.

[0094] After acute treatment, e.g., treatment resulting in relief of one or more symptoms of RA or a reduction in DAS28 score (e.g., less than 2.6 or less than 3.2), the subject may then transition to a long-term administration regimen, including, for example, a reduction in the dosage of the antibody or antigen-binding fragment thereof, a reduction in the frequency of administration, or both, relative to the acute treatment. For example, chronic treatment may include intravenous or subcutaneous administration of the antibody or antigen-binding fragment thereof, e.g., once every 4 weeks, once every 2 weeks, or once a week, at a dosage of, e.g., about 1 mg / kg to about 5 mg / kg (e.g., about 1 mg / kg, 1.5 mg / kg, 2 mg / kg, 2.5 mg / kg, 3 mg / kg, 3.5 mg / kg, 4 mg / kg, 4.5 mg / kg, or 5 mg / kg). Such a long-term administration regimen may reduce the overall dosage administered to the subject while still maintaining therapeutic efficacy.

[0095] A subject may be transitioned from acute to chronic dosing (e.g., if a relief is observed in one or more RA symptoms) or from chronic to acute dosing (e.g., if a worsening of one or more RA symptoms is observed) one or more times during treatment with an anti-CD40 antibody or antigen-binding fragment thereof, as appropriate, for example, based on RA symptoms observed in the subject.

[0096] In certain embodiments, the subject is identified as a responder to treatment with an anti-CD40 antibody or antigen-binding fragment thereof and as having a statistically significant improvement in disease activity, where disease activity is determined by one or more criteria selected from the group consisting of ACR20, ACR50, ACR70, DAS28, DAS28-CRP, Physician Global Assessment of Disease Activity (PhGA), Health Assessment Questionnaire-Disability Index (HAQ-DI), Short Form Health Survey (SF-36) in Physical Health Composite Score (PCS) and Mental Health Composite Score (MCS), SF-36 Total Composite Score (TCS), Clinical Disease Activity Index (CDAI), SDAI (calculated from CDAI+DAS28-CRP), and visual analog scale (VAS) for pain. In certain embodiments, the subject achieves a significant improvement in ACR20 response to KPL-404 versus placebo by week 12, week 24, or week 52 of treatment. In other embodiments, the subject achieves a significant improvement in ACR50 response to KPL-404 versus placebo by week 12, 24, or 52 of treatment. In certain embodiments, the subject achieves a significant improvement in DAS28-CRP response to KPL-404 versus placebo by week 12, 24, or 52 of treatment.

[0097] Combination therapy The pharmaceutical compositions administered in the methods described herein can be administered alone or in combination with one or more other therapeutic agents (e.g., a second therapeutic agent). In some embodiments, a pharmaceutical composition comprising an anti-CD40 antibody or antigen-binding fragment thereof can further comprise a second therapeutic agent, e.g., either conjugated or unconjugated to the antibody or fragment thereof. In one embodiment, the second agent is another monoclonal or polyclonal antibody or antigen-binding fragment thereof. In another embodiment, the second agent is an immunosuppressant. In one embodiment, the second agent is a cytotoxic or cytostatic agent. In another embodiment, the second agent can target a receptor or receptor complex other than CD40 on the surface of activated lymphocytes, dendritic cells, or CD40-expressing cancer cells.

[0098] Such combination therapy may have additive or synergistic effects on disease parameters (eg, severity of symptoms, number of symptoms, or frequency of recurrences).

[0099] The pharmaceutical composition may be administered simultaneously with a second therapeutic agent, hi another specific embodiment, the second therapeutic agent is administered before or after administration of the pharmaceutical composition containing the anti-CD40 antibody or antigen-binding fragment thereof.

[0100] The pharmaceutical composition may be formulated or administered in combination with disease-modifying antirheumatic drugs (DMARDs), for example, for the treatment of rheumatoid arthritis.For example, the pharmaceutical composition may be administered with one or more of abatacept, adalimumab, anakinra, apremilast, azathioprine, baricitinib, certolizumab pegol, chloroquine, cyclosporine (cyclosporine A), D-penicillamine, etanercept, filgotinib, golimumab, gold salts (e.g., gold sodium thiomalate or auranofin), hydroxychloroquine, infliximab, leflunomide, methotrexate, minocycline, rituximab, sarilumab, secukinumab, sulfasalazine, tocilizumab, tofacitinib, and ustekinumab.

[0101] In some embodiments, the DMARD is a conventional synthetic DMARD. The pharmaceutical compositions containing the antibodies or antigen-binding fragments described herein may be formulated or administered in combination with an immunosuppressant. Examples of immunosuppressants include, but are not limited to, calcineurin inhibitors (e.g., cyclosporines such as cyclosporine A (SANDIMMUNE®) and cyclosporine G), tacrolimus (PROGRAF®, PROTOPIC®), mTor inhibitors (e.g., sirolimus (RAPAMUNE®, NEORAL®), temsirolimus (TORISEL®), zotarolimus, and everolimus (CERTICAN®). mark), fingolimod (GILENYA™), myriocin, alemtuzumab (CAMPATH®, MABCAMPATH®, CAMPATH-1H®), rituximab (RITUXAN®, MABTHERA®), anti-CD4 monoclonal antibodies (e.g., HuMax-CD4), anti-LFA1 monoclonal antibodies (e.g., CD11a), anti-LFA3 monoclonal antibodies, anti-CD45 antibodies (e.g., anti-CD45RB antibodies), anti-CD19 antibodies ( See, e.g., U.S. Patent Publication No. 2006 / 0280738), monabatacept (Orencia®), belatacept, indolyl-ASC (a 32-indole ether derivative of tacrolimus and ascomycin), azathioprine (AZASAN®, IMURAN®), lymphocyte immunoglobulin and antithymocyte globulin [horse] (ATGAM®), mycophenolate mofetil (CELLCEPT®), mycophenolate sodium (M YFORTIC®), daclizumab (ZENAPAX®), basiliximab (SIMULECT®), cyclophosphamide (ENDOXAN®, CYTOXAN®, NEOSAR™, PROCYTOX™, REVIMMUNE™), prednisone, prednisolone, leflunomide (ARAVA®), FK778, FK779, 15-deoxyspergualin (DSG), busulfan (MYLERAN®,BUSULFEX®), fludarabine (FLUDARA®), methotrexate (RHEUMATREX®, TREXALL®), etanercept (ENBREL®), adalimumab (HUMIRA®), 6-mercaptopurine (PURINETHOL®), 15-deoxyspergualin (gusperimus), LF15-0195, bredinin, brequinar, and muromonab-CD3 (ORTHOCLONE®).

[0102] The pharmaceutical compositions containing the antibodies or antigen-binding fragments described herein can be formulated or administered in combination with a Janus kinase (JAK) inhibitor.The JAK inhibitor can be, for example, ruxolitinib, tofacitinib, oclacitinib, baricitinib, peficitinib, fedratinib, upadacitinib, filgotinib, or delgocitinib.

[0103] Pharmaceutical compositions containing the antibodies or antigen-binding fragments described herein can be formulated or administered in combination with a corticosteroid (eg, prednisone).

[0104] The antibody or antigen-binding fragment thereof and the second therapeutic agent (eg, an anti-rheumatic agent) can be administered within one month or one week apart. EXAMPLES

[0105] The following examples of specific embodiments for carrying out the present disclosure are offered for illustrative purposes only and are not intended to limit the scope of the disclosure in any way. EXAMPLES

[0106] PK Analysis and Modeling of KPL-404 to Identify Long-Term Dosing Regimens in Patients with Rheumatoid Arthritis In a first-in-human, phase 1, single-dose escalation study, 52 healthy subjects received a single dose of KPL-404 either subcutaneously (SC) or intravenously (IV) without any dose-limiting safety findings, infectious episodes, or toxicity. The study demonstrated that at 10 mg / kg IV, complete receptor occupancy (RO) was observed through day 71, with complete suppression of T cell-dependent antibody responses (TDAR) to keyhole limpet hemocyanin challenge on day 1 and rechallenge from days 29 to 57. At 5 mg / kg SC, complete RO was observed through day 43, with complete suppression of TDAR through at least day 29. Complete suppression of anti-drug antibodies (ADA) to KPL-404, an independent indicator of target binding, was also observed, accompanied by serum concentrations of KPL-404 exceeding approximately 0.1-0.2 μg / mL that persisted for at least 50 and 57 days following administration of 5 mg / kg SC and 10 mg / kg IV, respectively.

[0107] OBJECTIVE: To use phase 1 and nonclinical data to identify long-term dosing regimens that produce sub-, sub-, and supra-therapeutic PK to be utilized in a phase 2 multiple-ascending dose study.

[0108] method The PK model was used to simulate multiple dosing scenarios including 2.5, 5, and 10 mg / kg SC qwk, q2wk, and q4wk, and 10 mg / kg IV q4wk. The PK model was used to identify treatment dosing schedules by generating 1000 virtual subjects with parameter estimates including intersubject variability. After SC dosing, all subjects were predicted to achieve complete ADA suppression at ≥2.5 mg / kg SC q2wk over the entire dosing interval.

[0109] result At 2 mg / kg SC q2wk (starting dose level), simulated steady-state 8-week data predicted PK below the therapeutic range for most subjects, with approximately 31-fold and 18-fold margin of safety compared to the preclinical NOAEL dose. At 5 mg / kg SC q2wk, 100% of patients were predicted to be within the therapeutic range, representing a potential practical effective dose level. At 10 mg / kg SC q2wk, 100% of patients were predicted to be above the therapeutic range.

[0110] Following SC dosing, all subjects were expected to achieve complete ADA suppression at ≥2.5 mg / kg SC q2wk over the entire dosing interval.

[0111] At 2 mg / kg SC q2wk (starting dose level), 8-week simulated steady-state data predicted subtherapeutic PK for most subjects and approximately 31- and 18-fold margins of safety compared to the preclinical NOAEL dose.

[0112] At 5 mg / kg SC q2wk, 100% of patients were predicted to be within the effective therapeutic window, indicating a potentially practical effective dose level.

[0113] At 10 mg / kg SC q2wk, 100% of patients were predicted to be in or above the therapeutic window. These results support the design of a Phase 2, multiple ascending dose (MAD) study with a PK lead-in consisting of three cohorts (randomized 6:2) of 2, 5, or 10 mg / kg SC q2wk, and a proof-of-concept phase (cohort 4) consisting of 48-60 subjects randomized 1:1:1 to 10 mg / kg, 5 mg / kg, and placebo SC q2wk (Figure 1). The study was designed to evaluate the efficacy (disease activity in 28 joints using C-reactive protein (DAS28-CRP)), safety, PK, and pharmacodynamics (PD) of dose-escalating levels of KPL-404 compared to placebo in patients with moderate-to-severe RA (bDMARD-IR or JAKi-IR). The study also allows for optional cohort flexibility to include additional dosing regimens and / or subpopulations identified based on clinical response and biomarkers.

[0114] conclusion Inhibition of CD40-CD154 costimulatory interactions can be utilized to manage the spectrum of rheumatoid arthritis (RA). KPL-404 demonstrated sustained absorption / excretion capable of suppressing TDAR over an extended period of time, allowing the use of extended dosing intervals regardless of IV or SC administration. These analyses demonstrate the efficacy and safety of KPL-404 in treating RA, especially in long-term dosing regimens. EXAMPLES

[0115] A study to evaluate the safety, pharmacokinetics (PK), and efficacy of KPL-404 in subjects with rheumatoid arthritis (RA) who have had an inadequate response to or are intolerant to at least one biologic disease-modifying rheumatic drug (bDMARD) or Janus kinase inhibitor (JAKi)

[0116] Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease of unknown etiology. RA is characterized by an inflammatory process manifested by persistent symmetric polyarthritis of synovial joints, which may ultimately lead to bone erosion, deformity, and disability. If left untreated or inappropriately treated, progressive functional impairment with increasing disability occurs, leading to a decreased ability to perform activities of daily living, resulting in a reduced quality of life. The prevalence of RA in the general population is approximately 1% and increases with age in both genders, with women more likely to develop RA than men. Standard of care treatment includes early treatment with disease-modifying antirheumatic drugs (DMARDs), including conventional synthetic DMARDs (csDMARDs) (e.g., methotrexate, sulfasalazine, hydroxychloroquine, and leflunomide). Over the past two decades, targeted biologic DMARDs (bDMARDs) have significantly transformed the treatment paradigm for RA, with treatment optimized until clinical remission or minimal disease activity is achieved. bDMARDs have significantly improved clinical, functional, and radiological outcomes in subjects with RA. Despite the broad therapeutic armamentarium of bDMARDs, blockade of any single cytokine or cell subset has not demonstrated disease control in all RA subjects. In randomized controlled trials and clinical practice, approximately 30%-40% of treated subjects demonstrate an inadequate response to bDMARDs, fail to maintain a good response over time, or experience adverse events (AEs) that lead to treatment discontinuation. Many of these subjects with an inadequate response or intolerance to one or more bDMARDs have previously failed multiple csDMARDs and have few treatment options, and treatment of the disease in this population remains a significant unmet need in the management of RA.

[0117] The safety, pharmacokinetics (PK), and pharmacodynamics (PD) of KPL-404 were evaluated in a single-dose escalation study in healthy subjects. Initially, KPL-404 will be administered subcutaneously (SC) every other week (q2wk) at doses up to 10 mg / kg. Once safety and tolerability have been established in cohorts 1, 2, and 3, cohort 4 will be designed to evaluate the efficacy of KPL-404 using an increased number of treated subjects (cohorts 1-3 will have approximately 24 subjects, cohort 4 will have up to 60 subjects, and additional cohorts may be tested). Efficacy will be assessed using the change from baseline in 28-joint Disease Activity Score with C-reactive protein (DAS28-CRP) at week 12 as the primary endpoint. Additional cohorts may be initiated at doses and regimens that do not exceed the systemic exposure associated with a dosing regimen of 10 mg / kg q2wk.

[0118] Administration The starting dose for Cohort 1 was selected based on the following factors:

[0119] Safety profile of single-ascending dose study in healthy subjects: Single doses up to 10 mg / kg IV and 5 mg / kg SC were evaluated. There were no deaths or related serious adverse events [SAEs], with a patella fracture due to a fall being the only serious event. No dose-limiting toxicities were observed.

[0120] Analysis of pharmacokinetic data from previous studies with KPL-404 showed that the C associated with a 3.0 mg / kg IV dose max and AUC 0-∞ were approximately 3.1-fold and 4.7-fold lower, respectively, than the 10 mg / kg IV dose. max and at the end of the dosing interval (AUC 0-t) are approximately 7- and 8-fold lower than the 10 mg / kg single IV dosing regimen in Phase 1 studies. Furthermore, starting doses ≤2.0 mg / kg SC are expected to show lower variability compared to lower doses (≤1 mg / kg) because the impact of target-mediated pharmacokinetics (TMDD) on the PK profile is expected to be minimal.

[0121] KPL-404 was evaluated in 8-week and 26-week repeat-dose toxicity studies in cynomolgus monkeys. The only adverse findings in the study were early discontinuation at day 143 in one female given 97 mg / kg SC after several days of clinical signs of ill health, and one other female given 97 mg / kg SC exhibited bilateral uveitis associated with small thrombi in the anterior chamber. The no observed adverse effect level (NOAEL) was 12-fold higher than the starting dose in this Phase 2 study, and the systemic exposure associated with the NOAEL via the SC route was approximately 10.6-fold higher. This provides a sufficient margin of safety between the proposed dose ranges in this study compared to nonclinical safety findings.

[0122] Benefit / Risk Assessment Results from nonclinical studies and a completed Phase 1 study indicate that KPL-404 at doses up to 10 mg / kg administered every other week is safe. Given subject populations that have failed to achieve adequate responses to other RA treatments, PK, and safety data from Phase 1 first-in-human studies, as well as nonclinical data, KPL-404 may improve outcomes in subjects with RA who are at low risk for significant adverse events (e.g., previously non-responding subjects). [Table 2-1]

[0123] [Table 2-2] Clinical trial plan Overall study design The overall scheme of the trial is shown in Figure 1. A detailed overview of procedures and activities is provided in Table 3. [Table 3-1] [Table 3-2] [Table 3-3]

[0124] KPL-404 treatment will be explored in a 28-week (up to 4-week screening period, 12-week treatment period, and 12-week safety follow-up period) multicenter, randomized, double-blind, placebo-controlled, multiple-dose study with a PK lead-in designed to evaluate the safety, PK, efficacy, and PD of KPL-404 in subjects with moderately to severely active RA who have had an inadequate response or are intolerant to a JAKi or at least one bDMARD. Subjects treated with both a bDMARD and a JAKi will be excluded from the study. The objectives of the study are to evaluate safety, efficacy, and PD compared to placebo across the estimated therapeutic window and to characterize PK across various dose levels of KPL-404.

[0125] Subjects will enter a screening period (days -28 to -1) before returning for the randomization visit and administration of the first dose (day 1). Subjects may be rescreened only once, at the discretion of the Investigator and with approval of the Medical Monitor. Abnormal laboratory values ​​may, in certain cases, be repeated with approval of the Medical Monitor without requiring rescreening. If a subject is rescreened, they will be provided with a new subject number and clinical laboratory evaluations may be repeated once, if necessary.

[0126] All subjects will receive an SC injection of the investigational drug (IP) at the investigational site on Day 1. In the first three cohorts, subjects will be randomized in a 3:1 ratio to the following escalating doses: Cohort 1: 2 mg / kg KPL-404 or placebo, every other week (q2wk) (n=8) Cohort 2: 5 mg / kg KPL-404 or placebo q2wk (n=8) Cohort 3: 10 mg / kg KPL-404 q2wk or placebo (n=8)

[0127] Cohorts 1-3 will be initiated consecutively and will be evaluated in an open-label fashion to provide safety and tolerability data after all subjects have completed 12 weeks (at expected study status) and PK after all subjects have completed 8 weeks, respectively.

[0128] Following review of safety, tolerability, and PK data as described above, subjects will be enrolled into Cohort 4. Subjects in Cohort 4 will be randomized 1:1:1 to receive: 10 mg / kg KPL-404 q2wk (n=16–20) 5 mg / kg KPL-404 q2wk (n=16–20) Placebo q2wk (n=16–20)

[0129] Subjects will be observed for at least 60 minutes after the first dose and 30 minutes after each subsequent dose. If no safety concerns are identified during that time, subjects will be discharged from the investigational site after all study procedures are completed. All subjects will return to the investigational site for all treatment and safety follow-up visits according to the study schedule (Table 3) for determination of RA parameters, as well as evaluation of safety, tolerability, PK, biomarkers, and ADA.

[0130] An optional synovial biopsy substudy may be conducted at selected investigational sites. Participation in the substudy is voluntary. Synovial biopsies from subjects participating in the substudy will be collected at the time points described in the assessment schedule. Biopsy collection procedures and processing will be outlined in a separate manual.

[0131] If a subject discontinues early (i.e., before the End of Treatment visit), the subject will be encouraged to complete the End of Study Visit (Week 12) (within approximately 2 weeks after discontinuation of study drug), as well as any subsequent visits up to the Week 24 visit.

[0132] At the end of the 12-week treatment period, all subjects will be followed for safety for 30 days, during which adverse event (AE) data will be collected. All subjects will then be followed for an additional 8 weeks (total of 12 weeks off-treatment observation) to explore the longevity of any observed treatment effects, during which PK assessments and data on disease status and concomitant medications will be collected.

[0133] Number of subjects The study plans to enroll approximately 24 subjects in cohorts 1-3 and up to 60 subjects in cohort 4 across 100 investigational sites. Additional cohorts may be assigned and studied. All subjects will be randomized to study drug.

[0134] Subjects may discontinue treatment for any Grade 3 (severe) or any Grade 4 (life-threatening) TEAE, regardless of causality.

[0135] In this study, enrollment into a cohort will be suspended for review under any of the following circumstances: Two subjects experienced the same grade 3 TEAE One subject had a grade 4 (life-threatening) or grade 5 (fatal) TEAE

[0136] If appropriate, the study will be resumed after review of the TEAE.

[0137] Subject Selection and Withdrawal Subject selection criteria To participate in this study, subjects must meet all of the following criteria: 1. Adult male or female between the ages of 18 and 80 (inclusive). 2. Body weight ≥ 40 to ≤ 100 kg (all cohorts). 3. Patients had been diagnosed with RA for ≥3 months and met the 2010 American College of Rheumatology (ACR) / European League Against Rheumatism (EULAR) classification criteria for RA (classified as ACR RA functional class 1-3). 4.Treated with a biologic disease-modifying antirheumatic drug (bDMARD) or Janus kinase inhibitor (JAKi) for RA for ≥ 3 months and had an inadequate response or had to discontinue bDMARD or JAKi therapy due to poor tolerability or toxicity, regardless of treatment duration. 5.Currently receiving csDMARD treatment for ≥ 3 months and continuing for ≥ 4 weeks prior to first dose of study drug. a. The following csDMARDs are acceptable: oral or parenteral methotrexate ([MTX]; 7.5-25 mg / week), sulfasalazine (≤3000 mg / day), hydroxychloroquine (≤400 mg / day), chloroquine (≤250 mg / day), and leflunomide (≤20 mg / day). b. Combinations of up to two background csDMARDs are allowed, except for the combination of MTX and leflunomide. 6.Meet all of the following disease activity criteria: ≥6 swollen joints (based on a 66 joint count) and ≥6 tender joints (based on a 68 joint count) at the screening and baseline visits, b. High-sensitivity C-reactive protein level ≥ 5 mg / L (central laboratory); c. Serum RF and / or APA seropositivity at screening according to the central laboratory definition of positivity. 7. All bDMARDs or JAKis must be discontinued prior to the first dose of KPL-404. The washout period of bDMARDs or JAKis prior to the first dose of KPL-404 is specified below. For bDMARDs or JAKis not listed below, the washout shall be at least 5 times the mean elimination half-life of the drug: a. Etanercept: ≥ 4 weeks; b. Adalimumab, infliximab, certolizumab, golimumab, abatacept, tocilizumab, and sarilumab: ≥ 8 weeks; c. Rituximab, ≥ 1 year; d. For JAKi (either investigational or commercially available treatment), ≥ 2 weeks. 8. All strong opiate medications must be discontinued for at least 1 week prior to the first dose of KPL-404. 9. Females must be either postmenopausal, permanently surgically deprived of fertility, or, for females of childbearing potential, must practice at least one highly effective method of contraception that is effective from Study Day 1 through at least 30 days after the EOS visit (additional local requirements may apply). Sexually active female subjects are: Must be non-pregnant, dry, and agree to use highly effective contraception from the screening visit until 30 days after the EOS visit. NOTE: Highly effective methods of contraception include: Hormonal contraceptives that involve the inhibition of ovulation (continued for at least 4 weeks before the first dose) Intrauterine contraceptive device Intrauterine system Bilateral tubal occlusion Vasectomy for male partner ·Sexual abstinence 10. Sexually active male subjects must have documentation documenting a vasectomy or agree to use a highly effective method of contraception as described above with a fertile partner from the time of first dose until 30 days after the EOS visit. 11. Male subjects must agree to refrain from donating sperm from the first dose until 30 days after the last dose of study drug. Female subjects must agree to refrain from donating eggs from the first dose until 30 days after the EOS visit. 12. Females of childbearing potential must have a negative serum β-human chorionic gonadotropin (β-hCG) test at the screening visit and a negative urine pregnancy test on Day 1.

[0138] Subject Exclusion Criteria A subject cannot participate in the study if any of the following apply: 1. Subjects with a history of exposure to any other anti-CD40 / CD40L agent. 2.Subjects with a history of treatment with both DMARDs and JAKis. 3. Received treatment with injectable corticosteroids (including intra-articular) or oral prednisone or equivalent at a dose >10 mg / day within 8 weeks prior to randomization. (Note: Concomitant therapy with nonsteroidal anti-inflammatory drugs, acetaminophen, oral corticosteroids (equivalent to ≤10 mg / day prednisone), or inhaled corticosteroids at unchanged doses for ≥4 weeks prior to baseline for stable disease is permitted and must be maintained at unchanged doses throughout the study.) 4. The individual has received an investigational drug within 30 days or within 5 half-lives (whichever is longer) prior to the first dose of the investigational drug if the half-life is known. 5.Subjects who are concurrently enrolled in another clinical study (excluding observational studies). 6.Subjects who have undergone major surgery within 8 weeks prior to screening or are scheduled for major surgery within 6 months after baseline. 7. Recipient of an organ transplant (except for corneal transplantation <3 months prior to baseline). 8.Subject has received a live (attenuated) vaccine within 4 weeks prior to baseline or anticipated need for live vaccination during study participation, including 4 weeks after the last dose of KPL-404. 9. History of any arthritis with onset before age 16 years or current diagnosis of inflammatory joint disease other than RA, including but not limited to gout, systemic lupus erythematosus, psoriatic arthritis, axial spondyloarthropathy including ankylosing spondylitis and axial spondyloarthritis, reactive arthritis, overlap connective tissue disease, scleroderma, polymyositis, dermatomyositis, fibromyalgia (with current active symptoms). A current diagnosis of secondary Sjogren's syndrome is permitted. 10. Clinically significant active infection, including signs / symptoms suggestive of infection, any significant recurrent or chronic infection (including Hepatitis C virus seropositivity), or any infectious episode requiring hospitalization or treatment with an antibiotic (IV) within 12 weeks prior to screening or treatment with an oral anti-infective within 14 days prior to the first dose of KPL-404. Subjects with any opportunistic infection within 6 months prior to screening will be excluded from the study. 11. Subjects at high risk for infection (e.g., those with a history of inherited or acquired immunodeficiency), a history of an infected joint prosthesis at any time (where the prosthesis is still in situ), a lower extremity ulcer, an indwelling urinary catheter, or a persistent or recurrent pulmonary infection. 12. Subject has tested positive for Human Immunodeficiency Virus infection. 13. Subjects with chronic active Hepatitis B infection as defined below will be excluded from the study: aPeople who are positive for hepatitis B surface antigen. b Those who are positive for hepatitis B anti-core antibodies but negative for anti-surface antibodies. 14. Anyone with a positive (or two indeterminate) QuantiFERON® test result (if possible, testing should be performed at least 4 weeks after receiving the mRNA COVID-19 vaccine). 15. Subjects with a history of thromboembolic events or a significant risk for future thromboembolic events (defined as a confirmed diagnosis of thrombophilia or an unstable condition associated with an increased incidence of thrombosis, such as atrial fibrillation or the presence of antiphospholipid antibodies). Any history of thrombosis should be acknowledged by the medical monitor. 16.Subjects who have laboratory test values ​​that meet the following criteria during the KPL-404 screening period (prior to randomization): Serum aspartate aminotransferase >3 × upper limit of normal (ULN), B. serum alanine aminotransferase >3×ULN; C. Total bilirubin > 2 × ULN; d. Estimated glomerular filtration rate < 40mL / min / 1.73m using the 4-parameter MDRD (Modification of Diet in Renal Disease) simplified formula 2 , e. Absolute neutrophil count <1,500 / μL f. Hemoglobin < 9 g / dL g. Total white blood cell count <2,500 / μL, h. Platelet count <150,000 / μL, i. Absolute lymphocyte count <800 / μL. 17.Subjects with a known history of allergies or reactions to any component of KPL-404 or placebo formulation and / or other products in the same class. 18.Have a history of cancer within the past 5 years prior to screening, except for basal and squamous cell carcinoma of the skin, or in situ cancer of the cervix that has been treated and deemed cured. 19.Subject to a history of clinically significant drug or alcohol abuse within the past 6 months (as determined by the investigator). 20.Subjects with a history of any of the following cardiovascular conditions: Moderate to severe congestive heart failure (New York Heart Association class III or IV), b. Recent (within the past 6 months) cerebrovascular accident, myocardial infarction, or coronary stent placement; c. Uncontrolled hypertension defined by confirmed systolic blood pressure >160mmHg or diastolic blood pressure >100mmHg. 21.Subjects have clinically relevant or significant electrocardiogram (ECG) abnormalities, including an ECG with a QT interval corrected for heart rate (QTc) >500 msec. 22. Any condition that, in the opinion of the investigator, may interfere with the evaluation of KPL-404 or interpretation of subject safety or confound the outcome of the trial.

[0139] Treatment of the subject Explanation of the investigational drug [Table 4]

[0140] Randomization All subjects eligible to participate in the study will be randomized on Day 1 prior to study drug administration. Each subject will be randomized to receive KPL-404 or placebo according to the randomization schedule. Randomization will be stratified by prior treatment with bDMARDs or JAKis.

[0141] For cohorts 1-3, subjects will be randomized 3:1 to KPL-404 vs. placebo.

[0142] The overall randomization ratio for Cohort 4 is 1:1:1 (5 mg / kg, 10 mg / kg, placebo). Given the different volumes of the two active dose groups, to maintain blinding, two volumes of placebo were used matched to the corresponding 5 mg / kg and 10 mg / kg volumes, resulting in an effective randomization ratio of 2:2:1:1 with the last two numbers representing the two different volumes of placebo. Subjects who received both volumes of placebo are pooled in all analyses. Pharmacists and investigators are only unblinded to dose level (10 mg / kg vs. 5 mg / kg) and remain blinded to the overall treatment (active treatment vs. placebo).

[0143] Investigational Drug Materials and Management Investigational Drug The KPL-404 formulation is a monoclonal antibody consisting of two heavy chains and two light chains (i.e., a heavy chain variable region having the amino acid sequence of SEQ ID NO: 9 and a light chain variable region having the amino acid sequence of SEQ ID NO: 10) covalently linked by disulfide bridges. It binds to CD40 with an affinity of 7.2 nM and blocks CD154-mediated activation of B cells.

[0144] The placebo contained only the above excipients and no active ingredients.

[0145] Administration KPL-404 and placebo will be administered subcutaneously. There are no restrictions on fasting, water intake, or posture before or after administration.

[0146] Test evaluation Order of Evaluation The following assessments should be performed at pre-dose and post-dose time points, as appropriate, in the following order: 1. Subject-reported outcomes 2. Tender joint count (TJC) 68 / Swollen joint count (SJC) 66 and clinical evaluation 3.12-lead electrocardiogram 4. Chest X-ray (if needed, screening only) 5. Vital Signs 6.PK / PD Sampling 7. Blood collection for safety, efficacy, and biomarker assessments 8. Biopsy Samples (for subjects participating in the biopsy substudy) 9. Administration of investigational drug (if applicable) 10. Observation Period: Subjects will be observed for 60 minutes after dosing on Day 1 and for 30 minutes after dosing until the end of treatment.

[0147] Efficacy evaluation TJC / SJC 68 joints are examined and TJCs are assessed for tenderness and 66 joints are examined and SJCs are assessed for swelling. ACR response criteria are based on TJC68 / SJC66. The 68 joints (34 on each side of the subject's body) evaluated and classified as tender or non-tender include 2 temporomandibular joints, 2 sternoclavicular joints, 2 acromioclavicular joints, 2 shoulder joints, 2 elbow joints, 2 wrist joints, 10 metacarpophalangeal joints, 2 thumb interphalangeal joints, 8 proximal interphalangeal joints (of the hand), 8 distal interphalangeal joints (of the hand), 2 hip joints, 2 knee joints, 2 ankle joints, 2 ankle joints, 10 metatarsophalangeal joints, 2 thumbs (first proximal interphalangeal joint of the foot), and 8 proximal interphalangeal joints (of the foot). The 66 joints (33 on each side of the subject's body) that were assessed and classified as swollen or non-swollen included all 68 TJC joints except for two hip joints.

[0148] The DAS28-CRP, CDAI, and SDAI are based on the TJC28 / SJC28. 28 joints are examined and rated as tender or not tender for the TJCs and swollen or not swollen for the SJCs (Smolen 1995). The following 28 joints (14 on each side of the subject's body) are rated for tenderness and swelling: 8 proximal interphalangeal joints of the fingers, the thumb interphalangeal joint (n=2), 10 metacarpophalangeal joints plus wrist (n=2), elbow (n=2), shoulder (n=2), and knee (n=2).

[0149] The TJC and SJC will be conducted according to the test schedule in Table 3.

[0150] Doctor's overall evaluation The Physician Global Assessment of Disease Activity (PhGA) is a 100mm visual analog scale (VAS) that asks the investigator to rate the subject's current disease activity on a scale of 0mm (none) to 100mm (very active). This PhGA is used in the calculation of CDAI, SDAI, and ACR20 / 50 / 70. These indices are described, for example, in Arthritis Rheum. 15;57(2):193-202, 2007, Erratum in: Arthritis Rheum. 15;57(8):1574, 2007, and Smolen et al., Clin Exp Rheumatol. 23(5 Suppl 39):S100-8, 2005, the disclosures of each of which are incorporated herein by reference in their entirety.

[0151] Subject-reported outcomes Overall evaluation by subjects Subject Global Assessment of Disease Activity (PGA) is a measure of a subject's overall health status on a visual analog scale (VAS) with 0mm = best to 100mm = worst. This PGA is used in the calculation of DAS28-CRP, CDAI, SDAI, and ACR20 / 50 / 70 (see, e.g., Van Riel, Clin Exp Rheumatol. 34(5 Suppl 101):S40-S44, 2006, the disclosure of which is incorporated herein by reference in its entirety).

[0152] Visual Analogue Scale for Pain Subjects are asked to place a line perpendicular to the VAS line at the point that represents the most severe arthritis pain intensity using a scale of 0 to 100, with 0 indicating no pain and 100 indicating the worst pain. This pain VAS is used at baseline and at scheduled time points up to EOS.

[0153] Health Assessment Questionnaire-Disability Index The Health Assessment Questionnaire-Disability Index (HAQ-DI) consists of eight categories and considers a total of 20 specific functions that assess the subject's difficulty with activities of daily living over the past week. The categories include dressing and grooming, getting up, eating, walking, hygiene, reaching, grasping, and errands and chores. Also identified are specific aids or devices used for assistance and the assistance required from another person (assistance / assistance).

[0154] SF-36 Physical Health Composite Score The SF-36 measures eight domains of health-related quality of life within eight scales: 1) limitations in physical activity due to health problems, 2) limitations in social activities due to physical or emotional problems, 3) limitations in daily work activities due to physical health problems, 4) bodily pain, 5) general mental health (psychological distress and well-being), 6) limitations in daily work activities due to emotional problems, 7) vitality (energy and fatigue), and 8) perception of overall health. The domains are used to calculate composite scores-Physical Health Composite Score (PCS) and Mental Health Composite Score (MCS), as well as the SF-36 Total Composite Score (TCS). Scores on the SF-36 are based on a scale of 0 to 100, with zero representing the lowest possible score and 100 representing the highest possible score, with higher scores indicating better health.

[0155] Synovial biopsy substudy Synovial tissue biopsies are optional and will be performed in subjects who consent to the biopsy substudy to measure biomarkers in synovial tissue. Investigators have the option to collect biopsies according to the study schedule in Table 3. Details of synovial biopsy collection will be described in a separate manual.

[0156] Pharmacokinetic evaluation Pharmacokinetic (PK) blood samples will be collected by venipuncture or cannulation at the time points indicated in the study schedule in Table 3. Procedures for collection and processing of PK blood samples will be detailed in the clinical laboratory manual.

[0157] Serum concentrations of KPL-404 will be determined using a validated analytical procedure. Details of the analytical methodology will be described in a separate report.

[0158] Immunogenicity assessment All subjects will be monitored for the development of a humoral immune response to KPL-404. Blood samples will be assessed in all subjects for the presence of anti-KPL-404 antibodies (ADA) by a validated screening assay at baseline and according to the test schedule in Table 3.

[0159] The effect of ADA on the PK properties of KPL-404 in ADA positive subjects can be assessed.

[0160] Pharmacodynamic biomarker evaluation Circulating biomarker samples will be collected by venipuncture or cannulation at the time points indicated in the study schedule in Table 3. Procedures for collection and processing of biomarker blood samples will be detailed in the clinical laboratory manual.

[0161] statistical analysis

[0162] Statistics to be reported are outlined in this section. An analysis plan will be developed and approved prior to conducting the first interim analysis. All statistical analyses and reporting will be performed using SAS 9.4 or higher.

[0163] Where applicable, descriptive statistics and changes from baseline will be calculated for safety parameters.

[0164] Sample size justification The sample sizes for cohorts 1, 2, and 3 are based on safety and PK considerations. The sample size for cohort 4 is based on a two-sample t-test, which assumes a 1.2 point improvement in change from baseline in DAS28-CRP for KPL-404 over placebo (standard deviation = 1.3). Enrollment of 21 subjects in each of the three treatment arms (KPL-404 10 mg / kg, KPL-404 5 mg / kg, and placebo) will allow 90% power for a treatment comparison with a two-sided type I error of 0.1 if all subjects complete the 12-week DAS28-CRP assessment. To account for an expected discontinuation rate of 16%, each dose level will be achieved by enrolling 20 subjects per group in cohort 4 in addition to the 6 subjects per group enrolled in cohorts 1, 2, and 3. Cohorts 1, 2, and 3 would have already enrolled six subjects in each of the three treatment arms, so up to an additional 20 subjects per arm, and up to 60 subjects in total, would need to be enrolled in Cohort 4.

[0165] Efficacy Analysis: Efficacy Endpoints DAS28-CRP The primary endpoint for Cohort 4 and the secondary endpoint for Cohorts 1-3 was the change from baseline in DAS28-CRP at Week 12. The DAS28-CRP score was derived from the number of swollen joints (out of 28 assessed), the number of tender joints (out of 28 assessed), CRP level, and PGA score.

[0166] Low disease activity and complete response Low disease activity is defined as one of the following: DAS28-CRP < 3.2 ·CDAI < 10.0 SDAI < 11.0

[0167] A complete response was defined as one of the following: DAS28-CRP < 2.6 ·CDAI< 2.8 SDAI < 3.3

[0168] The clinical disease activity index (CDAI) is derived from the TJC / SJC of 28 joints, the PGA score, and the PhGA score. The SDAI is calculated from the CDAI+DAS28-CRP level.

[0169] ACR20 / 50 / 70 ACR20 / 50 / 70 corresponds to at least a 20%, 50%, or 70% improvement from baseline in tender joint counts (TJC68) and swollen joint counts (SJC66), and a corresponding improvement in three of the following five criteria: ·PGA ·Pain VAS ·PhGA ·HAQ-DI CRP level

[0170] Analysis method For efficacy analyses, a two-sided type I error probability of 0.1 will be used, where applicable.

[0171] Only descriptive statistics and listings will be produced for all efficacy parameters for Cohorts 1, 2, and 3. No formal statistical tests of efficacy will be performed.

[0172] For cohort 4 (pooled with cohorts 1, 2, and 3, as appropriate) and additional cohorts, if followed, analysis of covariance (ANCOVA) models will be used to compare the change from baseline in DAS28-CRP at week 12 for each of the KPL-404 dose groups and placebo. Baseline and randomization stratification factors will be included as covariates in the analysis of covariance models. No testing will be performed between the two KPL-404 dose groups. ACR response rates at week 12 between each of the KPL-404 dose groups and placebo will be compared using Fisher's exact test. Additionally, logistic regression models may be generated including key baseline characteristics as covariates in addition to treatment.

[0173] Baseline is defined as the last pre-dose value on or before Day 1.

[0174] Pharmacokinetic analysis Descriptive statistics (arithmetic mean, standard deviation, minimum, median, maximum, geometric mean, and geometric coefficient of variation, as appropriate) will be listed and summarized for serum concentrations and PK parameters of KPL-404. Where these data are available, KPL-404 dose proportionality will be examined between dose groups. AUC 0-∞ , AUC 0-t , and C max Estimates are tested for dose proportionality using a power model approach or analysis of variance (ANOVA) model, as appropriate. Where these data are available, exposure to KPL-404 administered by SC injection is compared across dose levels. Log-transformed AUC 0-∞ and AUC 0-t Estimates are analyzed using an ANOVA model with group as a fixed effect. Depending on the characteristics of the data set, other analytical tests may be employed. Further details regarding the analysis are described in the SAP for the PK analysis. Additional exploratory and post-hoc analyses of the data may be performed as deemed appropriate.

[0175] Immunogenicity analysis Serum ADA titers will be enumerated and summarized. Correlations between serum anti-KPL-404 antibodies and KPL-404 concentrations and efficacy may also be evaluated, where appropriate. No formal hypothesis testing is planned.

[0176] Phase 2 Study Changes The scheme of the modified Phase 2 clinical trial is shown in Figure 2. The 12-week study was designed to provide PK data and an early signal of efficacy with extended dosing. For cohorts 1 and 2, each cohort will randomize 8 patients sequentially, and cohort 3 will randomize up to 75 patients. In cohort 1, subjects will receive 2 mg / kg SC every other week. In cohort 2, subjects will receive 5 mg / kg SC every other week. Subjects in cohort 3 will receive 5 mg / kg SC qwk, 5 mg / kg SC q2wk, or placebo SC. Cohorts 4-6 will not be used.

[0177] The patient population includes those with active RA who have an inadequate response to a Janus kinase inhibitor (JAKi) or at least one biological disease-modifying antirheumatic drug (bDMARD) or are intolerant to a Janus kinase inhibitor (JAKi) or at least one biological disease-modifying antirheumatic drug (bDMARD). Subjects who have failed both bDMARDs and JAKi are excluded from the study (for ease of study readout, the subject is expected to respond to treatment with an anti-CD40 antibody).

[0178] Disease criteria included ≥6 swollen joints and ≥6 tender joints at screening and baseline visits, high-sensitivity C-reactive protein levels of ≥5 mg / L, and seropositivity for serum RF and / or ACPA at screening.

[0179] In cohorts 1 and 2 (8 randomized patients), primary endpoints included the incidence of treatment-emergent adverse events (TEAEs) and pharmacokinetics (Cmax, AUC(0-t)), and secondary endpoints included change from baseline in DAS28-CRP at week 12.

[0180] In the supplemental cohort 3, the cohort will randomize up to 75 patients. The primary endpoint includes the change from baseline in DAS28-CRP at week 12. Secondary endpoints include the incidence of treatment-emergent adverse events (TEAEs) and pharmacokinetics (Cmax, AUC(0-t)). An additional SRC was added for enhanced safety monitoring during the study. EXAMPLES

[0181] Treatment of rheumatoid arthritis A male subject weighing 80 kg with rheumatoid arthritis can be treated with KPL-404 antibody according to the methods described herein. The subject is classified as an inadequate response to bDMARD (due to poor tolerability or toxicity) (bDMARD-IR) or an inadequate response to JAKi (JAKi-IR) regardless of the duration of treatment. The antibody is prescribed at a dose of 5 mg / kg every other week at 200 mg / mL. The subject is characterized using a visual analog scale (VAS) for pain, showing a baseline pain score of 90 (maximum 100 indicates the most severe pain). The subject is also evaluated using the SF-36 physical health composite score, reporting a baseline score of 10 (minimum 0 indicates poor health). The subject can be administered 2.0 mL of the formulation by subcutaneous injection once every two weeks for the 12-week treatment regimen. After 12 weeks of treatment, the subject's ACR50 score, ACR70 score, DAS28-CRP score, pain VAS score can be evaluated for improvement (e.g., a decrease to a VAS score of about 40 (minimum 0 indicates no pain)), and the subject's SF-36 score can be evaluated for improvement (e.g., an increase to a score of about 60 (maximum 100 indicates good health)).Treatment can be continued for another 12 weeks, and the subject's ACR50, ACR70, DAS28-CRP, VAS, and SF-36 scores can be evaluated for stability or further improvement.

[0182] Other embodiments Although particular embodiments of the present invention have been described and illustrated, such embodiments are merely illustrative of the invention and should not be construed as limiting the invention as interpreted according to the appended claims.

[0183] All publications and patent applications cited in this specification are incorporated by reference in their entirety for all purposes as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference for all purposes. Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to those skilled in the art in light of the teachings of the present invention that certain changes and modifications can be made without departing from the spirit or scope of the appended claims.

Claims

1. 1. A method of treating rheumatoid arthritis comprising administering to a human subject by infusion or intravenous or subcutaneous administration a pharmaceutical composition comprising a humanized anti-CD40 antibody or antigen-binding fragment thereof comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:9 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:10, wherein the antibody or antigen-binding fragment thereof is administered at a dosage of about 2 mg / kg to about 10 mg / kg at least once every two weeks or month.

2. The method of claim 1, wherein the pharmaceutical composition comprises the antibody or antigen-binding fragment thereof at a concentration of about 50 mg / mL to about 300 mg / mL.

3. 3. The method of claim 2, wherein the pharmaceutical composition comprises the antibody or antigen-binding fragment thereof at a concentration of about 200 mg / mL.

4. The method of any one of claims 1 to 3, wherein about 0.5 mL to about 5.0 mL of the pharmaceutical composition is administered to the subject.

5. 5. The method of claim 4, wherein a volume of about 2.0 mL of the pharmaceutical composition is administered to the subject.

6. 6. The method of any one of claims 1 to 5, wherein the antibody or antigen-binding fragment thereof is administered at a dosage of about 1 mg / kg, 1.5 mg / kg, 2 mg / kg, 2.5 mg / kg, 3 mg / kg, 3.5 mg / kg, 4 mg / kg, 4.5 mg / kg, 5 mg / kg, 6 mg / kg, 7 mg / kg, 8 mg / kg, 9 mg / kg, or 10 mg / kg.

7. 7. The method of claim 6, wherein the antibody or antigen-binding fragment thereof is administered intravenously at a dosage of about 1 mg / kg, 1.5 mg / kg, 2 mg / kg, 2.5 mg / kg, 3 mg / kg, 3.5 mg / kg, 4 mg / kg, 4.5 mg / kg, 5 mg / kg, 6 mg / kg, 7 mg / kg, 8 mg / kg, 9 mg / kg, or 10 mg / kg.

8. 7. The method of claim 6, wherein the antibody or antigen-binding fragment thereof is administered subcutaneously at a dosage of about 1 mg / kg, 1.5 mg / kg, 2 mg / kg, 2.5 mg / kg, 3 mg / kg, 3.5 mg / kg, 4 mg / kg, 4.5 mg / kg, 5 mg / kg, 6 mg / kg, 7 mg / kg, 8 mg / kg, 9 mg / kg, or 10 mg / kg.

9. 9. The method of any one of claims 1-8, wherein the composition is administered for a treatment regimen of at least 1 week, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 1 year or more, or until clinical remission or minimal disease activity is achieved.

10. 10. The method of any one of claims 1 to 9, wherein the antibody or antigen-binding fragment thereof is administered subcutaneously once a week or once every two weeks at a concentration of about 2 mg / kg, about 5 mg / kg, or about 10 mg / kg.

11. 11. The method of claim 10, wherein the composition is administered for a treatment regimen of about 12 weeks or more, or until clinical remission is achieved or minimal disease activity is achieved.

12. The method of any one of claims 1 to 11, further comprising administering a second agent.

13. 13. The method of claim 12, wherein the second agent is an immunosuppressant, a Janus kinase (JAK) inhibitor, or a disease-modifying antirheumatic drug (DMARD).

14. The immunosuppressant is a calcineurin inhibitor, tacrolimus, an mTor inhibitor, fingolimod, myriocin, alemtuzumab, rituximab, an anti-CD4 monoclonal antibody, an anti-LFA1 monoclonal antibody, an anti-LFA3 monoclonal antibody, an anti-CD45 antibody, an anti-CD19 antibody, monabatacept, belatacept, indolyl ASC; 14. The method of claim 13, which is azathioprine, lymphocyte immunoglobulin and antithymocyte globulin (horse), mycophenolate mofetil, mycophenolate sodium, daclizumab, basiliximab, cyclophosphamide, prednisone, prednisolone, leflunomide, FK778, FK779, 15-deoxyspergualin, busulfan, fludarabine, methotrexate, 6-mercaptopurine, 15-deoxyspergualin, LF15-0195, bredinin, brequinar, or muromonab-CD3.

15. 14. The method of claim 13, wherein the JAK inhibitor is ruxolitinib, tofacitinib, oclacitinib, baricitinib, peficitinib, fedratinib, upadacitinib, filgotinib, or delgocitinib.

16. 14. The method of claim 13, wherein the DMARD is abatacept, adalimumab, anakinra, apremilast, azathioprine, baricitinib, certolizumab pegol, chloroquine, cyclosporine (cyclosporine A), D-penicillamine, etanercept, filgotinib, golimumab, gold salts (e.g., gold sodium thiomalate or auranofin), hydroxychloroquine, infliximab, leflunomide, methotrexate, minocycline, rituximab, sarilumab, secukinumab, sulfasalazine, tocilizumab, tofacitinib, or ustekinumab.

17. 14. The method of claim 13, wherein the DMARD is a conventional synthetic DMARD.

18. The method of any one of claims 1 to 17, wherein the subject has had an inadequate response to or is intolerant to a JAK inhibitor or DMARD.

19. 19. The method of any one of claims 1 to 18, wherein a 20% improvement in the American College of Rheumatology Core Set Disease Index (ACR20) is achieved following treatment.

20. 19. The method of any one of claims 1 to 18, wherein a 50% improvement in the American College of Rheumatology Core Set Disease Index (ACR50) is achieved following treatment.

21. 20. The method of claim 19, wherein the ACR20 is achieved after about 1 week of the treatment regimen.

22. 20. The method of claim 19, wherein the ACR20 is achieved after about 24 weeks of a treatment regimen.

23. 20. The method of claim 19, wherein the ACR20 is achieved after about 52 weeks of a treatment regimen.

24. 21. The method of claim 20, wherein the ACR50 is achieved after about 12 weeks of a treatment regimen.

25. 21. The method of claim 20, wherein the ACR50 is achieved after about 24 weeks of a treatment regimen.

26. 21. The method of claim 20, wherein the ACR50 is achieved after about 52 weeks of a treatment regimen.

27. The method according to any one of claims 1 to 18, wherein a Disease Activity Score in 28 joints using C-reactive protein (DAS28-CRP) is achieved after treatment.

28. 28. The method of claim 27, wherein said DAS28-CRP is achieved after about 12 weeks of a treatment regimen.

29. 28. The method of claim 27, wherein said DAS28-CRP is achieved after about 24 weeks of a treatment regimen.

30. 28. The method of claim 27, wherein said DAS28-CRP is achieved after about 52 weeks of a treatment regimen.

31. 19. The method of any one of claims 1-18, wherein after treatment, the subject achieves an improvement in disease activity as determined by a criteria selected from the group consisting of ACR20, ACR50, ACR70, DAS28, DAS28-CRP, Physician's Global Assessment of Disease Activity (PhGA), Health Assessment Questionnaire-Disability Index (HAQ-DI), Short Form Health Survey (SF-36) on the physical health composite score (PCS) and mental health composite score (MCS), SF-36 total composite score (TCS), Clinical Disease Activity Index (CDAI), Simple Disease Activity Index (SDAI), and visual analog scale (VAS) for pain, and combinations thereof.

Citation Information

Cited By

  • Methods for Treating or Reducing the Risk of Transplant Rejection - Patent application

    JP2025502095A